Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,31838561,Objective response rates,Objective response rates were 50.0% (95% CI 37.4-62.6%) for Oral-VRL and 53.7% (95% CI 41.1-66.0%) for IV-VRL.,"Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31838561/),%,50.0,59,DB00361,Vinorelbine
,31838561,Objective response rates,Objective response rates were 50.0% (95% CI 37.4-62.6%) for Oral-VRL and 53.7% (95% CI 41.1-66.0%) for IV-VRL.,"Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31838561/),%,53.7,60,DB00361,Vinorelbine
,27557783,PFS,"Median PFS and OS were 4 months (95 % CI, 2.8-6.9) and 17.5 months (95 % CI, 10.8-24.5), respectively.","Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27557783/),month,4,6132,DB00361,Vinorelbine
,27557783,PFS,"Median PFS and OS were 4 months (95 % CI, 2.8-6.9) and 17.5 months (95 % CI, 10.8-24.5), respectively.","Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27557783/),month,17,6133,DB00361,Vinorelbine
,27557783,OS,"Median PFS and OS were 4 months (95 % CI, 2.8-6.9) and 17.5 months (95 % CI, 10.8-24.5), respectively.","Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27557783/),month,17,6134,DB00361,Vinorelbine
,27557783,Cmax,The mean plasma VNR Cmax ranged from 1 to 2.7 ng/ml (Tmax 1.1 h) and no evidence of drug accumulation was found.,"Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27557783/),[ng] / [ml],1 to 2.7,6135,DB00361,Vinorelbine
,27557783,Tmax,The mean plasma VNR Cmax ranged from 1 to 2.7 ng/ml (Tmax 1.1 h) and no evidence of drug accumulation was found.,"Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27557783/),h,1.1,6136,DB00361,Vinorelbine
,27557783,PFS,Increased PFS (11.3 vs. 2.8 months; P = 0.0298) was observed in patients with sB7-H3 levels <30.25 ng/mL.,"Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27557783/),month,11.3,6137,DB00361,Vinorelbine
,27557783,PFS,Increased PFS (11.3 vs. 2.8 months; P = 0.0298) was observed in patients with sB7-H3 levels <30.25 ng/mL.,"Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27557783/),month,2.8,6138,DB00361,Vinorelbine
,12389069,absolute bioavailability,"The mean absolute bioavailability was 36%, with moderate interindividual (CV=20%) and intraindividual (CV=19%) variability.",A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12389069/),%,36,12703,DB00361,Vinorelbine
,12389069,bioavailability (F,By means of the simultaneous analysis of oral and intravenous data the bioavailability (F=36%) and its associated variability were estimated.,A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12389069/),%,36,12704,DB00361,Vinorelbine
,8549031,clearance rate,A lower vinorelbine clearance rate was observed in the five patients with more than 75% LVRT (22.9 L/hr/m2) compared with the 10 patients with no liver metastases (48.0 L/hr/m2) and the 12 patients with 25% to 75% LVRT (45.3 L/hr/m2).,Pharmacokinetics of vinorelbine in patients with liver metastases. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549031/),[l] / [h·m2],22.9,16945,DB00361,Vinorelbine
,8549031,clearance rate,A lower vinorelbine clearance rate was observed in the five patients with more than 75% LVRT (22.9 L/hr/m2) compared with the 10 patients with no liver metastases (48.0 L/hr/m2) and the 12 patients with 25% to 75% LVRT (45.3 L/hr/m2).,Pharmacokinetics of vinorelbine in patients with liver metastases. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549031/),[l] / [h·m2],48.0,16946,DB00361,Vinorelbine
,8549031,clearance rate,A lower vinorelbine clearance rate was observed in the five patients with more than 75% LVRT (22.9 L/hr/m2) compared with the 10 patients with no liver metastases (48.0 L/hr/m2) and the 12 patients with 25% to 75% LVRT (45.3 L/hr/m2).,Pharmacokinetics of vinorelbine in patients with liver metastases. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549031/),[l] / [h],45,16947,DB00361,Vinorelbine
,11852999,absolute gran,"The median absolute granulocyte count nadir for all courses was 200 mm(-3) (range, 0.1-7700 mm(-3)), and the median time to this nadir was 9 days (range, 7-30).",Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11852999/),1/[(mm)^3],200,22892,DB00361,Vinorelbine
,11852999,time to this nadir,"The median absolute granulocyte count nadir for all courses was 200 mm(-3) (range, 0.1-7700 mm(-3)), and the median time to this nadir was 9 days (range, 7-30).",Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11852999/),d,9,22893,DB00361,Vinorelbine
,11852999,platelet nadir,"The median platelet nadir was 163 (range, 27-401 k), and the median time to this nadir was 8 days (range, 7-30).",Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11852999/),k,163,22894,DB00361,Vinorelbine
,11852999,time to this nadir,"The median platelet nadir was 163 (range, 27-401 k), and the median time to this nadir was 8 days (range, 7-30).",Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11852999/),d,8,22895,DB00361,Vinorelbine
,16988826,AUC dose,"Plasma and urine concentrations of LC and ALC from 11 patients on carboplatin therapy (1 h intravenous infusion; AUC dose 4.8 +/- 1.1 mg/ml min) in combination with docetaxel, paclitaxel or vinorelbine, were determined by high-performance liquid chromatography with fluorimetric detection.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[mg] / [min·ml],4.8,24369,DB00361,Vinorelbine
,16988826,plasma concentrations,"Before carboplatin therapy, the mean +/- SD plasma concentrations of LC and ALC were 47.8 +/- 10.9 and 7.04 +/- 1.04 nmoles/ml, respectively, and remained constant throughout the entire study period.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[nmoles] / [ml],47.8,24370,DB00361,Vinorelbine
,16988826,plasma concentrations,"Before carboplatin therapy, the mean +/- SD plasma concentrations of LC and ALC were 47.8 +/- 10.9 and 7.04 +/- 1.04 nmoles/ml, respectively, and remained constant throughout the entire study period.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[nmoles] / [ml],7.04,24371,DB00361,Vinorelbine
,16988826,urinary excretion,"In contrast, urinary excretion of LC and ALC, increased significantly during the chemotherapy from 115 +/- 105 to 480 +/- 348 micromoles/day (P < 0.01) and from 41 +/- 41 to 89 +/- 52 micromoles/day (P < 0.05) for LC and ALC, respectively, subsequently reverting to normal 6 days after the end of chemotherapy.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[μmoles] / [d],115,24372,DB00361,Vinorelbine
,16988826,urinary excretion,"In contrast, urinary excretion of LC and ALC, increased significantly during the chemotherapy from 115 +/- 105 to 480 +/- 348 micromoles/day (P < 0.01) and from 41 +/- 41 to 89 +/- 52 micromoles/day (P < 0.05) for LC and ALC, respectively, subsequently reverting to normal 6 days after the end of chemotherapy.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[μmoles] / [d],480,24373,DB00361,Vinorelbine
,16988826,urinary excretion,"In contrast, urinary excretion of LC and ALC, increased significantly during the chemotherapy from 115 +/- 105 to 480 +/- 348 micromoles/day (P < 0.01) and from 41 +/- 41 to 89 +/- 52 micromoles/day (P < 0.05) for LC and ALC, respectively, subsequently reverting to normal 6 days after the end of chemotherapy.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[μmoles] / [d],41,24374,DB00361,Vinorelbine
,16988826,urinary excretion,"In contrast, urinary excretion of LC and ALC, increased significantly during the chemotherapy from 115 +/- 105 to 480 +/- 348 micromoles/day (P < 0.01) and from 41 +/- 41 to 89 +/- 52 micromoles/day (P < 0.05) for LC and ALC, respectively, subsequently reverting to normal 6 days after the end of chemotherapy.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[μmoles] / [d],89,24375,DB00361,Vinorelbine
,16988826,renal clearance,"Similarly, the renal clearance of LC and ALC increased substantially during chemotherapy from 1.67 +/- 1.43 to 9.05 +/- 9.52 ml/min (P < 0.05) and from 4.02 +/- 4.51 to 7.97 +/- 5.05 ml/min (P = not significant) for LC and ALC, respectively, reverting to normal 6 days after the end of chemotherapy.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[ml] / [min],1.67,24376,DB00361,Vinorelbine
,16988826,renal clearance,"Similarly, the renal clearance of LC and ALC increased substantially during chemotherapy from 1.67 +/- 1.43 to 9.05 +/- 9.52 ml/min (P < 0.05) and from 4.02 +/- 4.51 to 7.97 +/- 5.05 ml/min (P = not significant) for LC and ALC, respectively, reverting to normal 6 days after the end of chemotherapy.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[ml] / [min],9.05,24377,DB00361,Vinorelbine
,16988826,renal clearance,"Similarly, the renal clearance of LC and ALC increased substantially during chemotherapy from 1.67 +/- 1.43 to 9.05 +/- 9.52 ml/min (P < 0.05) and from 4.02 +/- 4.51 to 7.97 +/- 5.05 ml/min (P = not significant) for LC and ALC, respectively, reverting to normal 6 days after the end of chemotherapy.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[ml] / [min],4.02,24378,DB00361,Vinorelbine
,16988826,renal clearance,"Similarly, the renal clearance of LC and ALC increased substantially during chemotherapy from 1.67 +/- 1.43 to 9.05 +/- 9.52 ml/min (P < 0.05) and from 4.02 +/- 4.51 to 7.97 +/- 5.05 ml/min (P = not significant) for LC and ALC, respectively, reverting to normal 6 days after the end of chemotherapy.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[ml] / [min],7.97,24379,DB00361,Vinorelbine
,17051369,plasma AUC ratios,"The mean plasma concentration profile of vinorelbine administered with aprepitant was identical to that following vinorelbine administered alone, with geometric mean vinorelbine plasma AUC ratios of treatment B day 1/treatment A day 1 and of treatment B day 8/treatment A day of 1.01 (0.93, 1.10) and 1.00 (0.92, 1.08), respectively.",Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17051369/),,1.01,25530,DB00361,Vinorelbine
,17051369,plasma AUC ratios,"The mean plasma concentration profile of vinorelbine administered with aprepitant was identical to that following vinorelbine administered alone, with geometric mean vinorelbine plasma AUC ratios of treatment B day 1/treatment A day 1 and of treatment B day 8/treatment A day of 1.01 (0.93, 1.10) and 1.00 (0.92, 1.08), respectively.",Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17051369/),,1.00,25531,DB00361,Vinorelbine
,14634791,CL,"Typical population estimates of CL and central distribution volume (V(1)) were 74.2 l/h and 7.8 l, respectively.",Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14634791/),[l] / [h],74.2,27046,DB00361,Vinorelbine
,14634791,central distribution volume (V(1)),"Typical population estimates of CL and central distribution volume (V(1)) were 74.2 l/h and 7.8 l, respectively.",Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14634791/),l,7.8,27047,DB00361,Vinorelbine
,8400355,Cmax,"In the dog, NVB pharmacokinetic parameters, Cmax, tmax, AUC, t1/2 and Cl, were 49.0-1021.0 ng/ml, 1.14-3.69 h, 370.0-11754.5 ng/ml h, 19.3-64.3 h and 0.46-1.47 l/h/kg, respectively.",Pharmacokinetics of navelbine after oral administration in the dog and the monkey. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8400355/),[ng] / [ml],49.0-1021.0,27280,DB00361,Vinorelbine
,8400355,Cmax,"Pharmacokinetic parameters estimated from monkey data were essentially the same as those of the dog (Cmax, 877.6 mg/ml; tmax, 1.14 h; AUC, 7004.8 ng/ml h; t1/2, 18.2 h) except for Cl (10.40 l/h/kg), which was about 10-fold that of the dog.",Pharmacokinetics of navelbine after oral administration in the dog and the monkey. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8400355/),[mg] / [ml],877.6,27281,DB00361,Vinorelbine
,8400355,tmax,"Pharmacokinetic parameters estimated from monkey data were essentially the same as those of the dog (Cmax, 877.6 mg/ml; tmax, 1.14 h; AUC, 7004.8 ng/ml h; t1/2, 18.2 h) except for Cl (10.40 l/h/kg), which was about 10-fold that of the dog.",Pharmacokinetics of navelbine after oral administration in the dog and the monkey. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8400355/),h,1.14,27282,DB00361,Vinorelbine
,8400355,AUC,"Pharmacokinetic parameters estimated from monkey data were essentially the same as those of the dog (Cmax, 877.6 mg/ml; tmax, 1.14 h; AUC, 7004.8 ng/ml h; t1/2, 18.2 h) except for Cl (10.40 l/h/kg), which was about 10-fold that of the dog.",Pharmacokinetics of navelbine after oral administration in the dog and the monkey. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8400355/),[ng] / [h·ml],7004.8,27283,DB00361,Vinorelbine
,8400355,t1/2,"Pharmacokinetic parameters estimated from monkey data were essentially the same as those of the dog (Cmax, 877.6 mg/ml; tmax, 1.14 h; AUC, 7004.8 ng/ml h; t1/2, 18.2 h) except for Cl (10.40 l/h/kg), which was about 10-fold that of the dog.",Pharmacokinetics of navelbine after oral administration in the dog and the monkey. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8400355/),h,18.2,27284,DB00361,Vinorelbine
,8400355,Cl,"Pharmacokinetic parameters estimated from monkey data were essentially the same as those of the dog (Cmax, 877.6 mg/ml; tmax, 1.14 h; AUC, 7004.8 ng/ml h; t1/2, 18.2 h) except for Cl (10.40 l/h/kg), which was about 10-fold that of the dog.",Pharmacokinetics of navelbine after oral administration in the dog and the monkey. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8400355/),[l] / [h·kg],10.40,27285,DB00361,Vinorelbine
,3664483,plasma clearance,"The pharmacokinetics of navelbine were characterized by a high plasma clearance (0.27 to 1.49 liter.h-1.kg-1), a large distribution volume (8.2 to 48.2 liter.kg-1), and a long terminal half-life (22.1 to 67.8 h).",Clinical pharmacokinetics of the antitumor drug navelbine (5'-noranhydrovinblastine). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3664483/),[l] / [h·kg],0.27 to 1.49,27883,DB00361,Vinorelbine
,3664483,distribution volume,"The pharmacokinetics of navelbine were characterized by a high plasma clearance (0.27 to 1.49 liter.h-1.kg-1), a large distribution volume (8.2 to 48.2 liter.kg-1), and a long terminal half-life (22.1 to 67.8 h).",Clinical pharmacokinetics of the antitumor drug navelbine (5'-noranhydrovinblastine). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3664483/),[l] / [kg],8.2 to 48.2,27884,DB00361,Vinorelbine
,3664483,terminal half-life,"The pharmacokinetics of navelbine were characterized by a high plasma clearance (0.27 to 1.49 liter.h-1.kg-1), a large distribution volume (8.2 to 48.2 liter.kg-1), and a long terminal half-life (22.1 to 67.8 h).",Clinical pharmacokinetics of the antitumor drug navelbine (5'-noranhydrovinblastine). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3664483/),h,22.1 to 67.8,27885,DB00361,Vinorelbine
,12894568,peak concentrations,"The mean peak concentrations of vinorelbine were 274.2 ng/ml (Standard Deviation or SD: 90) and 458 ng/ml (SD: 448), the mean areas under the serum concentration-time curve were 8,344 ng.min.ml-1 (SD: 2,604) and 14,093 ng/ml.min-1 (SD: 10,000) and the total clearances were 1.146 l/min (SD: 0.333) and 1.003 l/min (SD: 0.714) when the Catharanthus alkaloid was given alone or was combined with rifampin, respectively.",The effect of rifampin on the pharmacokinetics of vinorelbine in the micropig. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12894568/),[ng] / [ml],274.2,28183,DB00361,Vinorelbine
,12894568,peak concentrations,"The mean peak concentrations of vinorelbine were 274.2 ng/ml (Standard Deviation or SD: 90) and 458 ng/ml (SD: 448), the mean areas under the serum concentration-time curve were 8,344 ng.min.ml-1 (SD: 2,604) and 14,093 ng/ml.min-1 (SD: 10,000) and the total clearances were 1.146 l/min (SD: 0.333) and 1.003 l/min (SD: 0.714) when the Catharanthus alkaloid was given alone or was combined with rifampin, respectively.",The effect of rifampin on the pharmacokinetics of vinorelbine in the micropig. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12894568/),[ng] / [ml],458,28184,DB00361,Vinorelbine
,12894568,areas under the serum concentration-time curve,"The mean peak concentrations of vinorelbine were 274.2 ng/ml (Standard Deviation or SD: 90) and 458 ng/ml (SD: 448), the mean areas under the serum concentration-time curve were 8,344 ng.min.ml-1 (SD: 2,604) and 14,093 ng/ml.min-1 (SD: 10,000) and the total clearances were 1.146 l/min (SD: 0.333) and 1.003 l/min (SD: 0.714) when the Catharanthus alkaloid was given alone or was combined with rifampin, respectively.",The effect of rifampin on the pharmacokinetics of vinorelbine in the micropig. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12894568/),[min·ng] / [ml],"8,344",28185,DB00361,Vinorelbine
,12894568,areas under the serum concentration-time curve,"The mean peak concentrations of vinorelbine were 274.2 ng/ml (Standard Deviation or SD: 90) and 458 ng/ml (SD: 448), the mean areas under the serum concentration-time curve were 8,344 ng.min.ml-1 (SD: 2,604) and 14,093 ng/ml.min-1 (SD: 10,000) and the total clearances were 1.146 l/min (SD: 0.333) and 1.003 l/min (SD: 0.714) when the Catharanthus alkaloid was given alone or was combined with rifampin, respectively.",The effect of rifampin on the pharmacokinetics of vinorelbine in the micropig. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12894568/),[ng] / [min·ml],"14,093",28186,DB00361,Vinorelbine
,12894568,total clearances,"The mean peak concentrations of vinorelbine were 274.2 ng/ml (Standard Deviation or SD: 90) and 458 ng/ml (SD: 448), the mean areas under the serum concentration-time curve were 8,344 ng.min.ml-1 (SD: 2,604) and 14,093 ng/ml.min-1 (SD: 10,000) and the total clearances were 1.146 l/min (SD: 0.333) and 1.003 l/min (SD: 0.714) when the Catharanthus alkaloid was given alone or was combined with rifampin, respectively.",The effect of rifampin on the pharmacokinetics of vinorelbine in the micropig. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12894568/),[l] / [min],1.146,28187,DB00361,Vinorelbine
,12894568,total clearances,"The mean peak concentrations of vinorelbine were 274.2 ng/ml (Standard Deviation or SD: 90) and 458 ng/ml (SD: 448), the mean areas under the serum concentration-time curve were 8,344 ng.min.ml-1 (SD: 2,604) and 14,093 ng/ml.min-1 (SD: 10,000) and the total clearances were 1.146 l/min (SD: 0.333) and 1.003 l/min (SD: 0.714) when the Catharanthus alkaloid was given alone or was combined with rifampin, respectively.",The effect of rifampin on the pharmacokinetics of vinorelbine in the micropig. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12894568/),[l] / [min],1.003,28188,DB00361,Vinorelbine
,1797198,Bioavailability,"Bioavailability (i.v./po) estimated from RIA and RA data averaged 40.6 and 93.0%, respectively.",Oral administration of [3H]navelbine in patients: comparative pharmacokinetics using radioactive and radioimmunologic determination methods. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797198/),%,40.6,29273,DB00361,Vinorelbine
,1797198,Bioavailability,"Bioavailability (i.v./po) estimated from RIA and RA data averaged 40.6 and 93.0%, respectively.",Oral administration of [3H]navelbine in patients: comparative pharmacokinetics using radioactive and radioimmunologic determination methods. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797198/),%,93.0,29274,DB00361,Vinorelbine
,11843245,MTD,"The MTD was 100 mg/m2/week due to the occurrence of dose-limiting neutropenia, nausea/vomiting and constipation in five of six patients.",Phase I and pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer (ABC). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11843245/),[mg] / [m2·week],100,30068,DB00361,Vinorelbine
,11843245,maximum blood concentration (Cmax),Vinorelbine was rapidly absorbed with maximum blood concentration (Cmax) of 103.8 +/- 41.6 ng x ml(-1) observed 1.2 +/- 0.8 hours (Tmax) after administration of 80 mg/m2.,Phase I and pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer (ABC). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11843245/),[ng] / [ml],103.8,30069,DB00361,Vinorelbine
,11843245,Tmax,Vinorelbine was rapidly absorbed with maximum blood concentration (Cmax) of 103.8 +/- 41.6 ng x ml(-1) observed 1.2 +/- 0.8 hours (Tmax) after administration of 80 mg/m2.,Phase I and pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer (ABC). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11843245/),h,1.2,30070,DB00361,Vinorelbine
,12357302,time to maximum concentration (T(max)),"The mean time to maximum concentration (T(max)) was shorter in fasted patients (1.63+/-0.98 h in blood, 1.67+/-0.96 h in plasma) than in fed patients (2.48+/-1.40 h in blood, 2.56+/-1.65 h in plasma) but these differences are not likely to modify the safety and/or efficacy of oral vinorelbine.",The effects of food on the pharmacokinetic profile of oral vinorelbine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357302/),h,1.63,31180,DB00361,Vinorelbine
,12357302,time to maximum concentration (T(max)),"The mean time to maximum concentration (T(max)) was shorter in fasted patients (1.63+/-0.98 h in blood, 1.67+/-0.96 h in plasma) than in fed patients (2.48+/-1.40 h in blood, 2.56+/-1.65 h in plasma) but these differences are not likely to modify the safety and/or efficacy of oral vinorelbine.",The effects of food on the pharmacokinetic profile of oral vinorelbine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357302/),h,1.67,31181,DB00361,Vinorelbine
,12357302,time to maximum concentration (T(max)),"The mean time to maximum concentration (T(max)) was shorter in fasted patients (1.63+/-0.98 h in blood, 1.67+/-0.96 h in plasma) than in fed patients (2.48+/-1.40 h in blood, 2.56+/-1.65 h in plasma) but these differences are not likely to modify the safety and/or efficacy of oral vinorelbine.",The effects of food on the pharmacokinetic profile of oral vinorelbine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357302/),h,2.48,31182,DB00361,Vinorelbine
,12357302,time to maximum concentration (T(max)),"The mean time to maximum concentration (T(max)) was shorter in fasted patients (1.63+/-0.98 h in blood, 1.67+/-0.96 h in plasma) than in fed patients (2.48+/-1.40 h in blood, 2.56+/-1.65 h in plasma) but these differences are not likely to modify the safety and/or efficacy of oral vinorelbine.",The effects of food on the pharmacokinetic profile of oral vinorelbine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357302/),h,2.56,31183,DB00361,Vinorelbine
∼,21749385,circulation t½,"The resulting vinorelbine circulation t½ was ∼ 9.47 h, which was greater than that of non-pegylated liposomes (∼ 5.55 h).",Encapsulation of vinorelbine into cholesterol-polyethylene glycol coated vesicles: drug loading and pharmacokinetic studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21749385/),h,9.47,31192,DB00361,Vinorelbine
,21749385,circulation t½,"The resulting vinorelbine circulation t½ was ∼ 9.47 h, which was greater than that of non-pegylated liposomes (∼ 5.55 h).",Encapsulation of vinorelbine into cholesterol-polyethylene glycol coated vesicles: drug loading and pharmacokinetic studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21749385/),h,5.55,31193,DB00361,Vinorelbine
,17947225,progression-free survival (PFS),"Median progression-free survival (PFS) was 4.6 months in arm A and 5.0 months in arm B, with PFS rates at 12 months of 0% and 15%, respectively.",Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17947225/),month,4.6,36048,DB00361,Vinorelbine
,17947225,progression-free survival (PFS),"Median progression-free survival (PFS) was 4.6 months in arm A and 5.0 months in arm B, with PFS rates at 12 months of 0% and 15%, respectively.",Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17947225/),month,5.0,36049,DB00361,Vinorelbine
,17947225,survival,Median survival was 7.3 months in arm A and 8.3 months in arm B.,Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17947225/),month,7.3,36050,DB00361,Vinorelbine
,17947225,survival,Median survival was 7.3 months in arm A and 8.3 months in arm B.,Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17947225/),month,8.3,36051,DB00361,Vinorelbine
,17545847,area under the curve (AUC),Chemotherapy-naïve patients with locally advanced or metastatic NSCLC were treated with carboplatin area under the curve (AUC) 6 mg/ml per minute intravenously on day 1 and vinorelbine 30 mg/m2 intravenously on days 1 and 8 every 3 weeks for four planned cycles.,A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17545847/),[mg] / [min·ml],6,36914,DB00361,Vinorelbine
,17545847,Overall response rate,Overall response rate was 27%.,A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17545847/),%,27,36915,DB00361,Vinorelbine
,17545847,survival,Median survival was 9.4 months (95% confidence interval: 6.1-18.0) with a 3-year survival rate of 20%.,A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17545847/),month,9,36916,DB00361,Vinorelbine
,31892325,objective response rate,"The objective response rate (complete response [CR] plus partial response [PR]) in heavily pre-treated HER2-positive MBC patients at the recommended doses of epertinib combined with trastuzumab was 67% (N = 9), with trastuzumab plus vinorelbine was 0% (N = 5) and with trastuzumab plus capecitabine was 56% (N = 9).",A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31892325/),%,67,38013,DB00361,Vinorelbine
,31892325,objective response rate,"The objective response rate (complete response [CR] plus partial response [PR]) in heavily pre-treated HER2-positive MBC patients at the recommended doses of epertinib combined with trastuzumab was 67% (N = 9), with trastuzumab plus vinorelbine was 0% (N = 5) and with trastuzumab plus capecitabine was 56% (N = 9).",A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31892325/),%,0,38014,DB00361,Vinorelbine
,31892325,objective response rate,"The objective response rate (complete response [CR] plus partial response [PR]) in heavily pre-treated HER2-positive MBC patients at the recommended doses of epertinib combined with trastuzumab was 67% (N = 9), with trastuzumab plus vinorelbine was 0% (N = 5) and with trastuzumab plus capecitabine was 56% (N = 9).",A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31892325/),%,56,38015,DB00361,Vinorelbine
,17551300,time-to-disease-progression,"Median time-to-disease-progression was 16.6 weeks (PO) versus 23.9 weeks (IV), and the median survival was 26 weeks (PO) versus 40.9 weeks IV vinorelbine.",Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17551300/),weeks,16.6,50554,DB00361,Vinorelbine
,17551300,time-to-disease-progression,"Median time-to-disease-progression was 16.6 weeks (PO) versus 23.9 weeks (IV), and the median survival was 26 weeks (PO) versus 40.9 weeks IV vinorelbine.",Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17551300/),weeks,23.9,50555,DB00361,Vinorelbine
,17551300,survival,"Median time-to-disease-progression was 16.6 weeks (PO) versus 23.9 weeks (IV), and the median survival was 26 weeks (PO) versus 40.9 weeks IV vinorelbine.",Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17551300/),weeks,26,50556,DB00361,Vinorelbine
,17551300,survival,"Median time-to-disease-progression was 16.6 weeks (PO) versus 23.9 weeks (IV), and the median survival was 26 weeks (PO) versus 40.9 weeks IV vinorelbine.",Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17551300/),weeks,40.9,50557,DB00361,Vinorelbine
,17551300,survival,Median survival on PO vinorelbine for patients with KPS 60-70 was 8.3 weeks versus 43 weeks (IV).,Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17551300/),weeks,8.3,50558,DB00361,Vinorelbine
,17551300,survival,Median survival on PO vinorelbine for patients with KPS 60-70 was 8.3 weeks versus 43 weeks (IV).,Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17551300/),weeks,43,50559,DB00361,Vinorelbine
,18594220,Time to progression,"Time to progression was 361 days, with 75.0% of liver metastases and 60% of lung metastases responding to this treatment.",Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II and pharmacokinetic study in Japan. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18594220/),d,361,58428,DB00361,Vinorelbine
,18948499,half-life in circulation,"The release rate of vinorelbine from the liposomal carrier was affected by both the chemical nature of the trapping agent and the resulting drug-to-lipid ratio, with liposomes prepared using sucrose octasulfate displaying the longest half-life in circulation (9.4 h) and in vivo retention in the nanoparticle (t(1/2) = 27.2 h).",Improved pharmacokinetics and efficacy of a highly stable nanoliposomal vinorelbine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18948499/),h,9.4,59765,DB00361,Vinorelbine
,18948499,t(1/2),"The release rate of vinorelbine from the liposomal carrier was affected by both the chemical nature of the trapping agent and the resulting drug-to-lipid ratio, with liposomes prepared using sucrose octasulfate displaying the longest half-life in circulation (9.4 h) and in vivo retention in the nanoparticle (t(1/2) = 27.2 h).",Improved pharmacokinetics and efficacy of a highly stable nanoliposomal vinorelbine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18948499/),h,27.2,59766,DB00361,Vinorelbine
,18948499,maximum tolerated dose,"Acute toxicity of the drug in immunocompetent mice slightly decreased upon encapsulation in liposomes, with a maximum tolerated dose of 17.5 mg VRL/kg for free vinorelbine and 23.8 mg VRL/kg for nanoliposomal vinorelbine.",Improved pharmacokinetics and efficacy of a highly stable nanoliposomal vinorelbine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18948499/),mg,17.5,59767,DB00361,Vinorelbine
,18948499,maximum tolerated dose,"Acute toxicity of the drug in immunocompetent mice slightly decreased upon encapsulation in liposomes, with a maximum tolerated dose of 17.5 mg VRL/kg for free vinorelbine and 23.8 mg VRL/kg for nanoliposomal vinorelbine.",Improved pharmacokinetics and efficacy of a highly stable nanoliposomal vinorelbine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18948499/),mg,23.8,59768,DB00361,Vinorelbine
,11334329,limits of quantitation,The limits of quantitation (LOQ) reached 0.5 ng/ml for both VNB and VNO and 1 ng/ml for DAV.,Sensitive determination of vinorelbine and its metabolites in human serum using liquid chromatography-electrospray mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11334329/),[ng] / [ml],0.5,59950,DB00361,Vinorelbine
,11334329,limits of quantitation,The limits of quantitation (LOQ) reached 0.5 ng/ml for both VNB and VNO and 1 ng/ml for DAV.,Sensitive determination of vinorelbine and its metabolites in human serum using liquid chromatography-electrospray mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11334329/),[ng] / [ml],1,59951,DB00361,Vinorelbine
,11334329,extraction recovery,"The method was proved linear in the range of LOQs up to 1000 ng/ml, and extraction recovery was 80% on average for the three compounds.",Sensitive determination of vinorelbine and its metabolites in human serum using liquid chromatography-electrospray mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11334329/),%,80,59952,DB00361,Vinorelbine
>,32614660,maximum loadability,"Results: Vinorelbine loading efficiency quickly reached 90% within 10 min with maximum loadability >90% by CB with both two sizes, and vinorelbine release rate gradually increased to ∼100% within 1 h.",Loadability and Releasing Profiles In Vitro and Pharmacokinetics In Vivo of Vinorelbine and Raltitrexed by CalliSpheres Beads. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32614660/),%,90,60654,DB00361,Vinorelbine
,7973765,terminal phase half-life,"There is a prolonged terminal phase due to relatively slow efflux of the drug from peripheral compartments, which results in a long terminal phase half-life, with average values ranging from 27.7 to 43.6 hours.",The clinical pharmacokinetics of vinorelbine (Navelbine). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7973765/),h,27.7 to 43.6,62420,DB00361,Vinorelbine
,7973765,absolute bioavailability,The absolute bioavailability of vinorelbine from this dosage form was 27% when intravenous doses of 30 mg/m2 were compared with oral doses of 100 mg/m2.,The clinical pharmacokinetics of vinorelbine (Navelbine). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7973765/),%,27,62421,DB00361,Vinorelbine
,27992451,response rate,The response rate was 30%.,Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27992451/),%,30,67410,DB00361,Vinorelbine
,15160284,total clearance,"In blood, the drug total clearance was about 0.6 l/h/kg, with minor contribution of renal clearance, steady state volume of distribution close to 13 l/h/kg, and elimination half-life at about 40 h.",Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study design. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15160284/),[l] / [h·kg],0.6,76620,DB00361,Vinorelbine
,15160284,steady state volume of distribution,"In blood, the drug total clearance was about 0.6 l/h/kg, with minor contribution of renal clearance, steady state volume of distribution close to 13 l/h/kg, and elimination half-life at about 40 h.",Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study design. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15160284/),[l] / [h·kg],13,76621,DB00361,Vinorelbine
,15160284,elimination half-life,"In blood, the drug total clearance was about 0.6 l/h/kg, with minor contribution of renal clearance, steady state volume of distribution close to 13 l/h/kg, and elimination half-life at about 40 h.",Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study design. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15160284/),h,40,76622,DB00361,Vinorelbine
,20809205,MTD,The MTD was 18.5 mg/m(2).,A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20809205/),[mg] / [m(2],18.5,79239,DB00361,Vinorelbine
,1742851,Tmax,"Absorption of navelbine was very rapid after oral administration: maximal drug concentrations were reached within the first 1 or 2 h (Tmax, 0.9-1.75 h; cmax, 70.9-832.6 ng/ml), with absorption constants ranging from 0.85 to 2.42 l/h.",Pharmacokinetics of navelbine after oral administration in cancer patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742851/),h,0.9-1.75,80851,DB00361,Vinorelbine
,1742851,cmax,"Absorption of navelbine was very rapid after oral administration: maximal drug concentrations were reached within the first 1 or 2 h (Tmax, 0.9-1.75 h; cmax, 70.9-832.6 ng/ml), with absorption constants ranging from 0.85 to 2.42 l/h.",Pharmacokinetics of navelbine after oral administration in cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742851/),[ng] / [ml],70.9-832.6,80852,DB00361,Vinorelbine
,1742851,absorption constants,"Absorption of navelbine was very rapid after oral administration: maximal drug concentrations were reached within the first 1 or 2 h (Tmax, 0.9-1.75 h; cmax, 70.9-832.6 ng/ml), with absorption constants ranging from 0.85 to 2.42 l/h.",Pharmacokinetics of navelbine after oral administration in cancer patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742851/),[l] / [h],0.85 to 2.42,80853,DB00361,Vinorelbine
,1742851,oral clearance,"The navelbine pharmacokinetic parameters obtained following oral administration were similar to those observed after i.v. bolus injection and were characterised by high oral clearance (0.43-1.45 1 h-1 kg-1), a large apparent volume of distribution (27.4-45.9 1/kg), and a long terminal half-life (24.2-56.5 h).",Pharmacokinetics of navelbine after oral administration in cancer patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742851/),[1] / [h·kg],0.43-1.45,80854,DB00361,Vinorelbine
,1742851,apparent volume of distribution,"The navelbine pharmacokinetic parameters obtained following oral administration were similar to those observed after i.v. bolus injection and were characterised by high oral clearance (0.43-1.45 1 h-1 kg-1), a large apparent volume of distribution (27.4-45.9 1/kg), and a long terminal half-life (24.2-56.5 h).",Pharmacokinetics of navelbine after oral administration in cancer patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742851/),[1] / [kg],27.4-45.9,80855,DB00361,Vinorelbine
,1742851,terminal half-life,"The navelbine pharmacokinetic parameters obtained following oral administration were similar to those observed after i.v. bolus injection and were characterised by high oral clearance (0.43-1.45 1 h-1 kg-1), a large apparent volume of distribution (27.4-45.9 1/kg), and a long terminal half-life (24.2-56.5 h).",Pharmacokinetics of navelbine after oral administration in cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742851/),h,24.2-56.5,80856,DB00361,Vinorelbine
,8083697,central volume of distribution,"Mean central volume of distribution and steady-state volume of distribution (Vss) were large (0.66 +/- 0.46 L/kg and 20.02 +/- 8.55 L/kg, respectively); the mean harmonic terminal half-life (t1/2) was long (18 hours); and the high mean clearance (CI) rate (0.80 +/- 0.68 L/h/kg) approached hepatic blood flow.","Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8083697/),[l] / [kg],0.66,81481,DB00361,Vinorelbine
,8083697,steady-state volume of distribution (Vss),"Mean central volume of distribution and steady-state volume of distribution (Vss) were large (0.66 +/- 0.46 L/kg and 20.02 +/- 8.55 L/kg, respectively); the mean harmonic terminal half-life (t1/2) was long (18 hours); and the high mean clearance (CI) rate (0.80 +/- 0.68 L/h/kg) approached hepatic blood flow.","Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8083697/),[l] / [kg],20.02,81482,DB00361,Vinorelbine
,8083697,terminal half-life (t1/2),"Mean central volume of distribution and steady-state volume of distribution (Vss) were large (0.66 +/- 0.46 L/kg and 20.02 +/- 8.55 L/kg, respectively); the mean harmonic terminal half-life (t1/2) was long (18 hours); and the high mean clearance (CI) rate (0.80 +/- 0.68 L/h/kg) approached hepatic blood flow.","Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8083697/),h,18,81483,DB00361,Vinorelbine
,8083697,clearance (CI) rate,"Mean central volume of distribution and steady-state volume of distribution (Vss) were large (0.66 +/- 0.46 L/kg and 20.02 +/- 8.55 L/kg, respectively); the mean harmonic terminal half-life (t1/2) was long (18 hours); and the high mean clearance (CI) rate (0.80 +/- 0.68 L/h/kg) approached hepatic blood flow.","Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8083697/),[l] / [h·kg],0.80,81484,DB00361,Vinorelbine
,8083697,F,"F was low (0.27 +/- 12), and absorption was rapid (mean time of maximum plasma concentration [Tmax], 0.91 +/- 0.22 hours).","Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8083697/),,0.27,81485,DB00361,Vinorelbine
,8083697,time of maximum plasma concentration [Tmax],"F was low (0.27 +/- 12), and absorption was rapid (mean time of maximum plasma concentration [Tmax], 0.91 +/- 0.22 hours).","Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8083697/),h,0.91,81486,DB00361,Vinorelbine
,8083697,F,"Absorption parameters after the first and second oral doses were similar, with mean F values of 0.27 +/- 0.14 and 0.25 +/- 0.11, respectively.","Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8083697/),,0.27,81487,DB00361,Vinorelbine
,8083697,F,"Absorption parameters after the first and second oral doses were similar, with mean F values of 0.27 +/- 0.14 and 0.25 +/- 0.11, respectively.","Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8083697/),,0.25,81488,DB00361,Vinorelbine
,8083697,nominal oral dose,"The mean nominal oral dose was 82 mg/m2, and the mean percentage of intended dose that was received was 92%.","Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8083697/),[mg] / [m2],82,81489,DB00361,Vinorelbine
,31354489,Cmax,"Mean vinorelbine Cmax values for ANX and Navelbine were 1,317.40 and 1,446.30 ng/mL, respectively.",A Phase I Comparative Pharmacokinetic and Safety Study of Two Intravenous Formulations of Vinorelbine in Patients With Advanced Non-Small Cell Lung Cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31354489/),[ng] / [ml],"1,317.40",83823,DB00361,Vinorelbine
,31354489,Cmax,"Mean vinorelbine Cmax values for ANX and Navelbine were 1,317.40 and 1,446.30 ng/mL, respectively.",A Phase I Comparative Pharmacokinetic and Safety Study of Two Intravenous Formulations of Vinorelbine in Patients With Advanced Non-Small Cell Lung Cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31354489/),[ng] / [ml],"1,446.30",83824,DB00361,Vinorelbine
,31354489,AUClast,"Corresponding AUClast values were 797.08 and 924.26 ng·h/mL, respectively.",A Phase I Comparative Pharmacokinetic and Safety Study of Two Intravenous Formulations of Vinorelbine in Patients With Advanced Non-Small Cell Lung Cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31354489/),[h·ng] / [ml],797.08,83825,DB00361,Vinorelbine
,31354489,AUClast,"Corresponding AUClast values were 797.08 and 924.26 ng·h/mL, respectively.",A Phase I Comparative Pharmacokinetic and Safety Study of Two Intravenous Formulations of Vinorelbine in Patients With Advanced Non-Small Cell Lung Cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31354489/),[h·ng] / [ml],924.26,83826,DB00361,Vinorelbine
,31354489,AUCinf,"AUCinf values were 830.14 and 957.16 ng·h/mL, respectively.",A Phase I Comparative Pharmacokinetic and Safety Study of Two Intravenous Formulations of Vinorelbine in Patients With Advanced Non-Small Cell Lung Cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31354489/),[h·ng] / [ml],830.14,83827,DB00361,Vinorelbine
,31354489,AUCinf,"AUCinf values were 830.14 and 957.16 ng·h/mL, respectively.",A Phase I Comparative Pharmacokinetic and Safety Study of Two Intravenous Formulations of Vinorelbine in Patients With Advanced Non-Small Cell Lung Cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31354489/),[h·ng] / [ml],957.16,83828,DB00361,Vinorelbine
,19694580,stability,The in vitro stability in human plasma at 37 degrees C for 72 hours was 83% +/- 3.5%.,Evaluation of pharmacokinetics of 111In-labeled VNB-PEGylated liposomes after intraperitoneal and intravenous administration in a tumor/ascites mouse model. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19694580/),%,83,85124,DB00361,Vinorelbine
,12926122,overall response rate,The overall response rate was 25% which included 1 of 24 complete responses (4%) and 4 of 24 partial responses (21%).,Gemcitabine and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12926122/),%,25,85985,DB00361,Vinorelbine
,12926122,response duration,"The median response duration was 5.5 months (2-16 months) and the overall median survival was 9 months (range, 2-25+).",Gemcitabine and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12926122/),month,5.5,85986,DB00361,Vinorelbine
,12926122,overall median survival,"The median response duration was 5.5 months (2-16 months) and the overall median survival was 9 months (range, 2-25+).",Gemcitabine and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12926122/),month,9,85987,DB00361,Vinorelbine
,10506711,overall response rate,The overall response rate was 16% (2 patients achieved a complete response and 5 patients achieved a partial response).,Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10506711/),%,16,97318,DB00361,Vinorelbine
,10506711,duration of response,The median duration of response was 4.3 months and the median overall survival was 8.6 months.,Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10506711/),month,4.3,97319,DB00361,Vinorelbine
,10506711,overall survival,The median duration of response was 4.3 months and the median overall survival was 8.6 months.,Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10506711/),month,8.6,97320,DB00361,Vinorelbine
,10506711,durations of response,Patients with visceral metastases and/or multiple sites of involvement had shorter durations of response than patients with only soft tissue disease or single-site metastasis (3.1 months vs. 4. 9 months) and shorter overall survival (8.1 months vs. 12 months).,Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10506711/),month,3.1,97321,DB00361,Vinorelbine
,10506711,durations of response,Patients with visceral metastases and/or multiple sites of involvement had shorter durations of response than patients with only soft tissue disease or single-site metastasis (3.1 months vs. 4. 9 months) and shorter overall survival (8.1 months vs. 12 months).,Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10506711/),month,4. 9,97322,DB00361,Vinorelbine
,10506711,overall survival,Patients with visceral metastases and/or multiple sites of involvement had shorter durations of response than patients with only soft tissue disease or single-site metastasis (3.1 months vs. 4. 9 months) and shorter overall survival (8.1 months vs. 12 months).,Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10506711/),month,8.1,97323,DB00361,Vinorelbine
,10506711,overall survival,Patients with visceral metastases and/or multiple sites of involvement had shorter durations of response than patients with only soft tissue disease or single-site metastasis (3.1 months vs. 4. 9 months) and shorter overall survival (8.1 months vs. 12 months).,Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10506711/),month,12,97324,DB00361,Vinorelbine
,11695718,tmax,"Peak serum concentrations occurred from 0.04 to 4.0 days after infusion (mean tmax = 1.79 +/- 1.55 d) with a mean cmax of 4,595 +/- 2,849 ng/ml.","Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695718/),d,1.79,102175,DB00361,Vinorelbine
,11695718,cmax,"Peak serum concentrations occurred from 0.04 to 4.0 days after infusion (mean tmax = 1.79 +/- 1.55 d) with a mean cmax of 4,595 +/- 2,849 ng/ml.","Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695718/),[ng] / [ml],"4,595",102176,DB00361,Vinorelbine
,11695718,Vp,"A total amount of 12.84 +/- 2.47 mg liposomal DOXO in the plasma volume (Vp = 2,794 + 537 ml) could be estimated at tmax (= 27 % of the mean dose of 47.6 mg).","Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695718/),ml,"2,794",102177,DB00361,Vinorelbine
,11695718,t 1/2el,Stealth liposomes were eliminated slowly from the blood with a mean t 1/2el of 1.9 + 0.5 days (MRT was 4.6 + 2.5 days).,"Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695718/),d,1.9,102178,DB00361,Vinorelbine
,11695718,MRT,Stealth liposomes were eliminated slowly from the blood with a mean t 1/2el of 1.9 + 0.5 days (MRT was 4.6 + 2.5 days).,"Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695718/),d,4.6,102179,DB00361,Vinorelbine
,11695718,AUClast,"AUClast values ranged from 8,070 to 33,446 ng/ml*d (mean 10,987 +/- 9,339 ng/ml*d).","Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695718/),[ng] / [d·ml],"8,070 to 33,446",102180,DB00361,Vinorelbine
,11695718,AUClast,"AUClast values ranged from 8,070 to 33,446 ng/ml*d (mean 10,987 +/- 9,339 ng/ml*d).","Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695718/),[ng] / [d·ml],"10,987",102181,DB00361,Vinorelbine
,11695718,plasma clearance (Cltot,"The low plasma clearance (Cltot = 4,681 +/- 2,835 ml/day) and the small volume of distribution (Vz = 11.7 +/- 6.31) suggested that stealth-liposomes were stable in the blood at least for 14 days.","Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695718/),[ml] / [d],"4,681",102182,DB00361,Vinorelbine
,11695718,volume of distribution (Vz,"The low plasma clearance (Cltot = 4,681 +/- 2,835 ml/day) and the small volume of distribution (Vz = 11.7 +/- 6.31) suggested that stealth-liposomes were stable in the blood at least for 14 days.","Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695718/),,11.7,102183,DB00361,Vinorelbine
,12451472,Hill constant,"In contrast, there was a highly significant relationship between the mean VRB AUC (days 1-5) and the absolute neutrophil count decrease (Emax model, Hill constant=4.38+/-2.59, EC(50)=508+/-53.2 micro g.h/l, r=0.75, P=0.0013).",The raltitrexed-vinorelbine combination: a phase I pharmacokinetic and pharmacodynamic trial in advanced breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12451472/),,4.38,106375,DB00361,Vinorelbine
,12451472,EC(50),"In contrast, there was a highly significant relationship between the mean VRB AUC (days 1-5) and the absolute neutrophil count decrease (Emax model, Hill constant=4.38+/-2.59, EC(50)=508+/-53.2 micro g.h/l, r=0.75, P=0.0013).",The raltitrexed-vinorelbine combination: a phase I pharmacokinetic and pharmacodynamic trial in advanced breast cancer. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12451472/),[h·μg] / [l],508,106376,DB00361,Vinorelbine
,9331121,area under the concentration-time curve (AUC),A phase I trial performed at the University of North Carolina was designed to evaluate paclitaxel 250 mg/m2 given over 24 hours plus escalating doses of carboplatin starting at an area under the concentration-time curve (AUC) dose of 8 supported by peripheral blood stem cells and filgrastim in the treatment of advanced NSCLC.,High-dose therapy with carboplatin and paclitaxel in non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9331121/),,8,106755,DB00361,Vinorelbine
,9331121,AUC,The maximum tolerated dose of carboplatin combined with paclitaxel 250 mg/m2 administered over 24 hours was defined at an AUC of 18.,High-dose therapy with carboplatin and paclitaxel in non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9331121/),,18,106756,DB00361,Vinorelbine
,9331121,AUC,This regimen is currently being tested in patients with locally advanced NSCLC by the Cancer and Leukemia Group B: patients receive two cycles of induction therapy with paclitaxel 250 mg/m2 over 3 hours followed by carboplatin at an AUC of 18 supported by peripheral blood stem cells and filgrastim.,High-dose therapy with carboplatin and paclitaxel in non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9331121/),,18,106757,DB00361,Vinorelbine
,29337963,PFS,"Median PFS was 14.6 and 15.9 weeks for patients treated at the MTDA and MTDB, including dose-escalation and expansion cohorts.",Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29337963/),weeks,14.6,114006,DB00361,Vinorelbine
,29337963,PFS,"Median PFS was 14.6 and 15.9 weeks for patients treated at the MTDA and MTDB, including dose-escalation and expansion cohorts.",Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29337963/),weeks,15.9,114007,DB00361,Vinorelbine
,16651648,Fractional survival,Fractional survival of neutrophils ranged from 1.3% to 100% and was significantly correlated with vinorelbine clearance (P < .01).,Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16651648/),%,1.3,122794,DB00361,Vinorelbine
,16651648,Fractional survival,Fractional survival of neutrophils ranged from 1.3% to 100% and was significantly correlated with vinorelbine clearance (P < .01).,Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16651648/),%,100,122795,DB00361,Vinorelbine
,12506167,overall response rate,"Four patients (6.9%) had complete responses, and 14 (24.1%) had partial responses, for an overall response rate of 31% (95% CI, 19% to 43%).",Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12506167/),%,31,127727,DB00361,Vinorelbine
,12506167,progression-free survival,Median progression-free survival was 17.4 weeks.,Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12506167/),weeks,17.4,127728,DB00361,Vinorelbine
,16163538,oral bioavailability,The oral bioavailability in wild-type was 16.0+/-1.4% (mean+/-SE) and was not significantly higher in mdr1a/1b (-/-) mice (17.9+/-0.7%).,The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16163538/),%,16.0,129278,DB00361,Vinorelbine
,16163538,oral bioavailability,The oral bioavailability in wild-type was 16.0+/-1.4% (mean+/-SE) and was not significantly higher in mdr1a/1b (-/-) mice (17.9+/-0.7%).,The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16163538/),%,17.9,129279,DB00361,Vinorelbine
,16163538,oral bioavailability,Because RTV increased the AUC of oral VRL by 83% the oral bioavailability was increased to 22.5+/-2.3% (p = 0.016).,The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16163538/),%,22.5,129280,DB00361,Vinorelbine
,1336784,areas under the curve,"In addition, the areas under the curve calculated from 1 hour (beginning of CDDP administration) to 72 hours were 414 ng.hour/mL (standard deviation [SD]: 94) (group NVB alone) and 407.1 ng.hour/mL (SD: 32.9) (group NVB + CDDP).",Clinical pharmacokinetics of vinorelbine alone and combined with cisplatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1336784/),[h·ng] / [ml],414,141056,DB00361,Vinorelbine
,1336784,areas under the curve,"In addition, the areas under the curve calculated from 1 hour (beginning of CDDP administration) to 72 hours were 414 ng.hour/mL (standard deviation [SD]: 94) (group NVB alone) and 407.1 ng.hour/mL (SD: 32.9) (group NVB + CDDP).",Clinical pharmacokinetics of vinorelbine alone and combined with cisplatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1336784/),[h·ng] / [ml],407.1,141057,DB00361,Vinorelbine
,8310715,terminal half-life,"2. In man, the pharmacokinetics of NVB are best characterized by a three-compartment model with a terminal half-life of 42 h and a large volume of distribution (75 l/kg).","Pharmacokinetic profile of vinorelbine, a new semi-synthetic vinca alkaloid, determined by high-performance liquid chromatography. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8310715/),h,42,141475,DB00361,Vinorelbine
,8310715,volume of distribution,"2. In man, the pharmacokinetics of NVB are best characterized by a three-compartment model with a terminal half-life of 42 h and a large volume of distribution (75 l/kg).","Pharmacokinetic profile of vinorelbine, a new semi-synthetic vinca alkaloid, determined by high-performance liquid chromatography. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8310715/),[l] / [kg],75,141476,DB00361,Vinorelbine
,8310715,total clearance,The total clearance was 1.26 lh-1 kg-1 and about 11% of the dose was eliminated by the kidneys.,"Pharmacokinetic profile of vinorelbine, a new semi-synthetic vinca alkaloid, determined by high-performance liquid chromatography. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8310715/),1/[kg·lh],1.26,141477,DB00361,Vinorelbine
,1607002,terminal half-life,The plasma concentration-time curves showed a tri-exponential decay with a long terminal half-life (44.7 h) and a high volume of distribution (Vz = 75.61.kg-1).,Pharmacokinetics of vinorelbine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1607002/),h,44.7,148319,DB00361,Vinorelbine
,1607002,volume of distribution (Vz,The plasma concentration-time curves showed a tri-exponential decay with a long terminal half-life (44.7 h) and a high volume of distribution (Vz = 75.61.kg-1).,Pharmacokinetics of vinorelbine in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1607002/),1/[kg],75.61,148320,DB00361,Vinorelbine
,1607002,CL,"The concentrations after the 8th infusion were significantly lower than after the 1st infusion, but without significant modification of CL (1.28 l.h-1.kg-1) or AUC (0.80 mg.l-1.h).",Pharmacokinetics of vinorelbine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1607002/),[l] / [h·kg],1.28,148321,DB00361,Vinorelbine
,1607002,AUC,"The concentrations after the 8th infusion were significantly lower than after the 1st infusion, but without significant modification of CL (1.28 l.h-1.kg-1) or AUC (0.80 mg.l-1.h).",Pharmacokinetics of vinorelbine in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1607002/),[h·mg] / [l],0.80,148322,DB00361,Vinorelbine
,7888700,CED,The CED of NVB was provisionally decided to be 4.8 mg/kg based on the comparison of AUC values at 24-infinity h between human patients and nude mice.,Evaluation of antitumor activity of navelbine (vinorelbine ditartrate) against human breast carcinoma xenografts based on its pharmacokinetics in nude mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7888700/),[mg] / [kg],4.8,149596,DB00361,Vinorelbine
,16912527,response rate,The response rate was 25.0% (3 PR/12).,[A phase-I clinical study of a combination therapy of vinorelbine and capecitabine in patients with advanced/recurrent breast cancer]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16912527/),%,25.0,152993,DB00361,Vinorelbine
,31559038,VRL,VRL was increased to 80 mg/m2 (arm A) or 30 mg/m2 (arm B) in cycles 2-4 in the absence of toxicity.,"A randomised, multicentre open-label phase II study to evaluate the efficacy, tolerability and pharmacokinetics of oral vinorelbine plus cisplatin versus intravenous vinorelbine plus cisplatin in Chinese patients with chemotherapy-naive unresectable or metastatic non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31559038/),[mg] / [m2],80,155076,DB00361,Vinorelbine
,31559038,VRL,VRL was increased to 80 mg/m2 (arm A) or 30 mg/m2 (arm B) in cycles 2-4 in the absence of toxicity.,"A randomised, multicentre open-label phase II study to evaluate the efficacy, tolerability and pharmacokinetics of oral vinorelbine plus cisplatin versus intravenous vinorelbine plus cisplatin in Chinese patients with chemotherapy-naive unresectable or metastatic non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31559038/),mg,30,155077,DB00361,Vinorelbine
,31559038,Disease control rate,"Disease control rate was 72.7% in arm A, 72.3% in arm B.","A randomised, multicentre open-label phase II study to evaluate the efficacy, tolerability and pharmacokinetics of oral vinorelbine plus cisplatin versus intravenous vinorelbine plus cisplatin in Chinese patients with chemotherapy-naive unresectable or metastatic non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31559038/),%,72.7,155078,DB00361,Vinorelbine
,31559038,Disease control rate,"Disease control rate was 72.7% in arm A, 72.3% in arm B.","A randomised, multicentre open-label phase II study to evaluate the efficacy, tolerability and pharmacokinetics of oral vinorelbine plus cisplatin versus intravenous vinorelbine plus cisplatin in Chinese patients with chemotherapy-naive unresectable or metastatic non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31559038/),%,72.3,155079,DB00361,Vinorelbine
,31559038,overall survival,Median overall survival was 16.1 months in arm A and 19.0 months in arm B.,"A randomised, multicentre open-label phase II study to evaluate the efficacy, tolerability and pharmacokinetics of oral vinorelbine plus cisplatin versus intravenous vinorelbine plus cisplatin in Chinese patients with chemotherapy-naive unresectable or metastatic non-small cell lung cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31559038/),month,16.1,155080,DB00361,Vinorelbine
,31559038,overall survival,Median overall survival was 16.1 months in arm A and 19.0 months in arm B.,"A randomised, multicentre open-label phase II study to evaluate the efficacy, tolerability and pharmacokinetics of oral vinorelbine plus cisplatin versus intravenous vinorelbine plus cisplatin in Chinese patients with chemotherapy-naive unresectable or metastatic non-small cell lung cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31559038/),month,19.0,155081,DB00361,Vinorelbine
,31559038,progression-free survival,Median progression-free survival was 4.6 months in arm A and 4.9 months in arm B.,"A randomised, multicentre open-label phase II study to evaluate the efficacy, tolerability and pharmacokinetics of oral vinorelbine plus cisplatin versus intravenous vinorelbine plus cisplatin in Chinese patients with chemotherapy-naive unresectable or metastatic non-small cell lung cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31559038/),month,4.6,155082,DB00361,Vinorelbine
,31559038,progression-free survival,Median progression-free survival was 4.6 months in arm A and 4.9 months in arm B.,"A randomised, multicentre open-label phase II study to evaluate the efficacy, tolerability and pharmacokinetics of oral vinorelbine plus cisplatin versus intravenous vinorelbine plus cisplatin in Chinese patients with chemotherapy-naive unresectable or metastatic non-small cell lung cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31559038/),month,4.9,155083,DB00361,Vinorelbine
less,17719191,cumulative distribution,"The VRL-loaded LMs had a particle size of 180.5+/-35.2nm with a 90% cumulative distribution less than 244.1nm, while the drug entrapment efficiency was 96.8%, and it remained stable for 12 months at 6+/-2 degrees C.","A lipid microsphere vehicle for vinorelbine: Stability, safety and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17719191/),n,244,159067,DB00361,Vinorelbine
,17719191,entrapment efficiency,"The VRL-loaded LMs had a particle size of 180.5+/-35.2nm with a 90% cumulative distribution less than 244.1nm, while the drug entrapment efficiency was 96.8%, and it remained stable for 12 months at 6+/-2 degrees C.","A lipid microsphere vehicle for vinorelbine: Stability, safety and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17719191/),%,96.8,159068,DB00361,Vinorelbine
,10602901,overall response rate,Vinorelbine (VNR) is highly active in metastatic breast cancer (MBC) and has shown an overall response rate of 40%-50% as first-line treatment.,Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: A phase I-II clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10602901/),%,40,159547,DB00361,Vinorelbine
,10602901,overall response rate,Vinorelbine (VNR) is highly active in metastatic breast cancer (MBC) and has shown an overall response rate of 40%-50% as first-line treatment.,Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: A phase I-II clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10602901/),%,50,159548,DB00361,Vinorelbine
,10602901,overall response rate,"The overall response rate was 36.5% with a CR rate of 4.8% (two of 41 patients, all at the highest dose level) and a PR rate of 31.7% (13 of 41 patients).",Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: A phase I-II clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10602901/),%,36.5,159549,DB00361,Vinorelbine
,10602901,CR rate,"The overall response rate was 36.5% with a CR rate of 4.8% (two of 41 patients, all at the highest dose level) and a PR rate of 31.7% (13 of 41 patients).",Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: A phase I-II clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10602901/),%,4.8,159550,DB00361,Vinorelbine
,10602901,PR rate,"The overall response rate was 36.5% with a CR rate of 4.8% (two of 41 patients, all at the highest dose level) and a PR rate of 31.7% (13 of 41 patients).",Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: A phase I-II clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10602901/),%,31.7,159551,DB00361,Vinorelbine
,10602901,response duration,The median response duration was 7.0 months (range 2-13 months).,Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: A phase I-II clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10602901/),month,7.0,159552,DB00361,Vinorelbine
,16111453,elimination half-life,Oral vinorelbine is rapidly absorbed (1.5-3 hours) with an elimination half-life of approximately 40 hours.,Oral versus intravenous vinorelbine: clinical safety profile. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16111453/),h,40,161157,DB00361,Vinorelbine
,16111453,absolute bioavailability,"It shows a low level of binding to plasma proteins (13%), is highly bound to platelets (78%) and has a hepatic metabolism and an absolute bioavailability of 40% with a moderate and similar interpatient variability for the two forms.",Oral versus intravenous vinorelbine: clinical safety profile. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16111453/),%,40,161158,DB00361,Vinorelbine
,16111453,absolute bioavailability,The absolute bioavailability is close to 38% in elderly whereas it is close to 40% in younger patients.,Oral versus intravenous vinorelbine: clinical safety profile. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16111453/),%,38,161159,DB00361,Vinorelbine
,16111453,absolute bioavailability,The absolute bioavailability is close to 38% in elderly whereas it is close to 40% in younger patients.,Oral versus intravenous vinorelbine: clinical safety profile. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16111453/),%,40,161160,DB00361,Vinorelbine
,16111453,absolute bioavailability,"As compared to the intravenous drug, oral vinorelbine demonstrated linear pharmacokinetics as well an absolute bioavailability of approximately 40%, and a reliable dose-correspondence of 80 mg/m2 oral form --> 30 mg/m2 i.v. and 60 mg/m2 oral --> 25 mg/m2 i.v.",Oral versus intravenous vinorelbine: clinical safety profile. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16111453/),%,40,161161,DB00361,Vinorelbine
,8995494,time of maximum plasma concentration (Tmax),"The mean time of maximum plasma concentration (Tmax) increased from 1.3 +/- 1.6 h in the fasting state to 2.5 +/- 1.6 h in the fed state, although this difference was not statistically significant.",The effects of food and divided dosing on the bioavailability of oral vinorelbine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8995494/),h,1.3,164461,DB00361,Vinorelbine
,8995494,time of maximum plasma concentration (Tmax),"The mean time of maximum plasma concentration (Tmax) increased from 1.3 +/- 1.6 h in the fasting state to 2.5 +/- 1.6 h in the fed state, although this difference was not statistically significant.",The effects of food and divided dosing on the bioavailability of oral vinorelbine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8995494/),h,2.5,164462,DB00361,Vinorelbine
,16001165,Total body clearance,Total body clearance calculated from the intravenous dose was 43.65 L/h (+/-10.9) and the terminal half-life was estimated to be 49 h.,The absolute bioavailability of oral vinorelbine in patients with solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16001165/),[l] / [h],43.65,169108,DB00361,Vinorelbine
,16001165,terminal half-life,Total body clearance calculated from the intravenous dose was 43.65 L/h (+/-10.9) and the terminal half-life was estimated to be 49 h.,The absolute bioavailability of oral vinorelbine in patients with solid tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16001165/),h,49,169109,DB00361,Vinorelbine
,16001165,absolute bioavailability,"Using complete data from the remaining 19 subjects, the mean absolute bioavailability of the oral dosage formulation of vinorelbine was calculated to be 33% (+/-18%).",The absolute bioavailability of oral vinorelbine in patients with solid tumors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16001165/),%,33,169110,DB00361,Vinorelbine
,16001165,oral bioavailability,In conclusion we have characterized the pharmacokinetics of both orally administered and intravenous vinorelbine over 7 days after administration and have determined the mean oral bioavailability of this oral formulation to be 33%.,The absolute bioavailability of oral vinorelbine in patients with solid tumors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16001165/),%,33,169111,DB00361,Vinorelbine
,7735488,sensitivity,"This method used a new internal standard, teniposide, that permitted a good compromise between sensitivity and retention times (10.6 and 15.5 min for teniposide and vinorelbine, respectively).",Determination of vinorelbine in rabbit plasma by high-performance liquid chromatography with coulometric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7735488/),min,10.6,169602,DB00361,Vinorelbine
,7735488,retention times,"This method used a new internal standard, teniposide, that permitted a good compromise between sensitivity and retention times (10.6 and 15.5 min for teniposide and vinorelbine, respectively).",Determination of vinorelbine in rabbit plasma by high-performance liquid chromatography with coulometric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7735488/),min,15.5,169603,DB00361,Vinorelbine
,7735488,extraction efficiency,The extraction efficiency was approximately 80% for both vinorelbine and the internal standard.,Determination of vinorelbine in rabbit plasma by high-performance liquid chromatography with coulometric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7735488/),%,80,169604,DB00361,Vinorelbine
,7735488,limit of detection,"Using coulometric detection, the limit of detection in plasma (400 microliters) was 1 ng/ml.",Determination of vinorelbine in rabbit plasma by high-performance liquid chromatography with coulometric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7735488/),[ng] / [ml],1,169605,DB00361,Vinorelbine
,22633624,overall response rate (ORR),"In rhabdomyosarcoma (RMS) (n=50), the best overall response rate (ORR) was 36% with four complete (8%) and 14 partial responses (28%).",Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: good tolerance profile and efficacy in rhabdomyosarcoma--a report from the Société Française des Cancers et leucémies de l'Enfant et de l'adolescent (SFCE). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22633624/),%,36,171487,DB00361,Vinorelbine
,9626924,V1,"The population mean values (CV%) of V1, k10, k12, k21, k13, k31, CL, t1/2gamma were respectively 21 l (55%), 3.2 h(-1) (29%), 7.7 h(-1) (74%), 1.3 h(-1) (67%), 4.7 h(-1) (53%), 0.04 h(-1) (20%), 57 l x h(-1) (31%) and 43 h (36%).",Bayesian pharmacokinetic estimation of vinorelbine in non-small-cell lung cancer patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626924/),l,21,173478,DB00361,Vinorelbine
,9626924,t1/2gamma,"The population mean values (CV%) of V1, k10, k12, k21, k13, k31, CL, t1/2gamma were respectively 21 l (55%), 3.2 h(-1) (29%), 7.7 h(-1) (74%), 1.3 h(-1) (67%), 4.7 h(-1) (53%), 0.04 h(-1) (20%), 57 l x h(-1) (31%) and 43 h (36%).",Bayesian pharmacokinetic estimation of vinorelbine in non-small-cell lung cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626924/),1/[h],0.04,173479,DB00361,Vinorelbine
,9626924,t1/2gamma,"The population mean values (CV%) of V1, k10, k12, k21, k13, k31, CL, t1/2gamma were respectively 21 l (55%), 3.2 h(-1) (29%), 7.7 h(-1) (74%), 1.3 h(-1) (67%), 4.7 h(-1) (53%), 0.04 h(-1) (20%), 57 l x h(-1) (31%) and 43 h (36%).",Bayesian pharmacokinetic estimation of vinorelbine in non-small-cell lung cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626924/),[l] / [h],57,173480,DB00361,Vinorelbine
,9626924,t1/2gamma,"The population mean values (CV%) of V1, k10, k12, k21, k13, k31, CL, t1/2gamma were respectively 21 l (55%), 3.2 h(-1) (29%), 7.7 h(-1) (74%), 1.3 h(-1) (67%), 4.7 h(-1) (53%), 0.04 h(-1) (20%), 57 l x h(-1) (31%) and 43 h (36%).",Bayesian pharmacokinetic estimation of vinorelbine in non-small-cell lung cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626924/),h,43,173481,DB00361,Vinorelbine
,21519841,CL,"The final parameter estimates were as follows: CL = 24.9 L/h, V1 = 8.48 L, Q2 = 50.7 L/h, V2 = 1,320 L, Q3 = 66.1 L/h, and V3 = 62.4 L (Qi and Vi denote inter-compartmental clearance and peripheral volume of distribution, respectively), normalized for a 70-kg patient according to BW allometric scaling (CL is normalized for a 250,000 platelet count).",Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21519841/),[l] / [h],24.9,174812,DB00361,Vinorelbine
,21519841,V1,"The final parameter estimates were as follows: CL = 24.9 L/h, V1 = 8.48 L, Q2 = 50.7 L/h, V2 = 1,320 L, Q3 = 66.1 L/h, and V3 = 62.4 L (Qi and Vi denote inter-compartmental clearance and peripheral volume of distribution, respectively), normalized for a 70-kg patient according to BW allometric scaling (CL is normalized for a 250,000 platelet count).",Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21519841/),l,8.48,174813,DB00361,Vinorelbine
,21519841,Q2,"The final parameter estimates were as follows: CL = 24.9 L/h, V1 = 8.48 L, Q2 = 50.7 L/h, V2 = 1,320 L, Q3 = 66.1 L/h, and V3 = 62.4 L (Qi and Vi denote inter-compartmental clearance and peripheral volume of distribution, respectively), normalized for a 70-kg patient according to BW allometric scaling (CL is normalized for a 250,000 platelet count).",Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21519841/),[l] / [h],50.7,174814,DB00361,Vinorelbine
,21519841,V2,"The final parameter estimates were as follows: CL = 24.9 L/h, V1 = 8.48 L, Q2 = 50.7 L/h, V2 = 1,320 L, Q3 = 66.1 L/h, and V3 = 62.4 L (Qi and Vi denote inter-compartmental clearance and peripheral volume of distribution, respectively), normalized for a 70-kg patient according to BW allometric scaling (CL is normalized for a 250,000 platelet count).",Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21519841/),l,"1,320",174815,DB00361,Vinorelbine
,21519841,Q3,"The final parameter estimates were as follows: CL = 24.9 L/h, V1 = 8.48 L, Q2 = 50.7 L/h, V2 = 1,320 L, Q3 = 66.1 L/h, and V3 = 62.4 L (Qi and Vi denote inter-compartmental clearance and peripheral volume of distribution, respectively), normalized for a 70-kg patient according to BW allometric scaling (CL is normalized for a 250,000 platelet count).",Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21519841/),[l] / [h],66.1,174816,DB00361,Vinorelbine
,21519841,V3,"The final parameter estimates were as follows: CL = 24.9 L/h, V1 = 8.48 L, Q2 = 50.7 L/h, V2 = 1,320 L, Q3 = 66.1 L/h, and V3 = 62.4 L (Qi and Vi denote inter-compartmental clearance and peripheral volume of distribution, respectively), normalized for a 70-kg patient according to BW allometric scaling (CL is normalized for a 250,000 platelet count).",Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21519841/),l,62.4,174817,DB00361,Vinorelbine
,21519841,CL,"The population pharmacokinetic parameters were CL = 27.7 L/h, V = 357 L, and the absorption constant, ka = 0.44 h(-1).",Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21519841/),[l] / [h],27.7,174818,DB00361,Vinorelbine
,21519841,V,"The population pharmacokinetic parameters were CL = 27.7 L/h, V = 357 L, and the absorption constant, ka = 0.44 h(-1).",Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21519841/),l,357,174819,DB00361,Vinorelbine
,21519841,"absorption constant, ka","The population pharmacokinetic parameters were CL = 27.7 L/h, V = 357 L, and the absorption constant, ka = 0.44 h(-1).",Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21519841/),1/[h],0.44,174820,DB00361,Vinorelbine
,11855752,half-lives of,"The half-lives of the terminal part of the curves, determined from blood and plasma data, were of the same order of magnitude: 31-35 h.",Blood and plasma pharmacokinetics of vinorelbine in elderly patients with advanced metastatic cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11855752/),h,31-35,176031,DB00361,Vinorelbine
,11855752,total clearances,Mean total clearances were about 0.71 l/h/kg from plasma and 0.45 l/h/kg from blood.,Blood and plasma pharmacokinetics of vinorelbine in elderly patients with advanced metastatic cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11855752/),[l] / [h·kg],0.71,176032,DB00361,Vinorelbine
,11855752,total clearances,Mean total clearances were about 0.71 l/h/kg from plasma and 0.45 l/h/kg from blood.,Blood and plasma pharmacokinetics of vinorelbine in elderly patients with advanced metastatic cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11855752/),[l] / [h·kg],0.45,176033,DB00361,Vinorelbine
,11855752,ratio AUC(B)/AU,"The ratio AUC(B)/AUC(P) (AUC(B) and AUC(P) are the area under the concentration-time curve from blood and plasma data, respectively) averaged 1.7; it was comparable to the blood/plasma ratio of 1.6 that remained constant over the 72 h of the study.",Blood and plasma pharmacokinetics of vinorelbine in elderly patients with advanced metastatic cancer. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11855752/),,1.7,176034,DB00361,Vinorelbine
,33790554,zeta potential,"CoNP-lips had a spherical shape with uniform size distribution; the average particle size was 162.97±9.06 nm, and the average zeta potential was -13.02±0.22 mV.",Synergistic Antitumor Efficacy Mediated by Liposomal Co-Delivery of Polymeric Micelles of Vinorelbine and Cisplatin in Non-Small Cell Lung Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33790554/),m,-,176425,DB00361,Vinorelbine
,33790554,zeta potential,"CoNP-lips had a spherical shape with uniform size distribution; the average particle size was 162.97±9.06 nm, and the average zeta potential was -13.02±0.22 mV.",Synergistic Antitumor Efficacy Mediated by Liposomal Co-Delivery of Polymeric Micelles of Vinorelbine and Cisplatin in Non-Small Cell Lung Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33790554/),m,13.02,176426,DB00361,Vinorelbine
,1849042,Cmax,"NVB is characterized by a three compartmental kinetics, with a Cmax of 1130 +/- 139 (SEM) ng/ml.",Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1849042/),[ng] / [ml],1130,176738,DB00361,Vinorelbine
,1849042,total body clearance,"The total body clearance and apparent volume of distribution, as defined by high performance liquid chromatography, are 1.26 +/- 0.09 liter/h/kg (48.6 +/- 4.1 liters/h/m2) and 75.6 +/- 9.2 liters/kg (2918.4 +/- 307.2 liters/m2).",Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1849042/),[l] / [h·kg],1.26,176739,DB00361,Vinorelbine
,1849042,apparent volume of distribution,"The total body clearance and apparent volume of distribution, as defined by high performance liquid chromatography, are 1.26 +/- 0.09 liter/h/kg (48.6 +/- 4.1 liters/h/m2) and 75.6 +/- 9.2 liters/kg (2918.4 +/- 307.2 liters/m2).",Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1849042/),[l] / [kg],75.6,176740,DB00361,Vinorelbine
,1849042,apparent volume of distribution,"The total body clearance and apparent volume of distribution, as defined by high performance liquid chromatography, are 1.26 +/- 0.09 liter/h/kg (48.6 +/- 4.1 liters/h/m2) and 75.6 +/- 9.2 liters/kg (2918.4 +/- 307.2 liters/m2).",Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1849042/),[l] / [m2],2918.4,176741,DB00361,Vinorelbine
,16283312,Response rate,"Response rate was 30%, and disease stabilization rate was 64% (all dose levels included).",Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16283312/),%,30,177794,DB00361,Vinorelbine
,12852694,Response rates,"Response rates in patients with visceral and liver metastases were 57% and 50%, respectively.",Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/ relapsed metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12852694/),%,57,180748,DB00361,Vinorelbine
,12852694,Response rates,"Response rates in patients with visceral and liver metastases were 57% and 50%, respectively.",Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/ relapsed metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12852694/),%,50,180749,DB00361,Vinorelbine
,12852694,time to progression,"After a median follow-up of 24 months (13-36), median time to progression was 8.5 months and median overall survival 17 months.",Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/ relapsed metastatic breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12852694/),month,8.5,180750,DB00361,Vinorelbine
,12852694,overall survival,"After a median follow-up of 24 months (13-36), median time to progression was 8.5 months and median overall survival 17 months.",Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/ relapsed metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12852694/),month,17,180751,DB00361,Vinorelbine
,3698163,Clearance,"Clearance was found to parallel toxicity for all drugs: it increases from 0.19 1 h-1 kg-1 for vincristine to 0.41 for Na-formyl navelbine, 1.4 for vinblastine, 2.3 for navelbine, and 2.6 for deacetyl navelbine amide.",Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698163/),[1] / [h·kg],0.19,181891,DB00361,Vinorelbine
,3698163,Clearance,"Clearance was found to parallel toxicity for all drugs: it increases from 0.19 1 h-1 kg-1 for vincristine to 0.41 for Na-formyl navelbine, 1.4 for vinblastine, 2.3 for navelbine, and 2.6 for deacetyl navelbine amide.",Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698163/),[1] / [h·kg],0.41,181892,DB00361,Vinorelbine
,3698163,Clearance,"Clearance was found to parallel toxicity for all drugs: it increases from 0.19 1 h-1 kg-1 for vincristine to 0.41 for Na-formyl navelbine, 1.4 for vinblastine, 2.3 for navelbine, and 2.6 for deacetyl navelbine amide.",Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698163/),[1] / [h·kg],1.4,181893,DB00361,Vinorelbine
,3698163,Clearance,"Clearance was found to parallel toxicity for all drugs: it increases from 0.19 1 h-1 kg-1 for vincristine to 0.41 for Na-formyl navelbine, 1.4 for vinblastine, 2.3 for navelbine, and 2.6 for deacetyl navelbine amide.",Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698163/),[1] / [h·kg],2.3,181894,DB00361,Vinorelbine
,3698163,Clearance,"Clearance was found to parallel toxicity for all drugs: it increases from 0.19 1 h-1 kg-1 for vincristine to 0.41 for Na-formyl navelbine, 1.4 for vinblastine, 2.3 for navelbine, and 2.6 for deacetyl navelbine amide.",Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698163/),[1] / [h·kg],2.6,181895,DB00361,Vinorelbine
,3698163,Terminal half-lives,Terminal half-lives were longer for the Na-formyl-substituted alkaloids (around 13 h) than for the others (8-10 h).,Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698163/),h,13,181896,DB00361,Vinorelbine
,3698163,Terminal half-lives,Terminal half-lives were longer for the Na-formyl-substituted alkaloids (around 13 h) than for the others (8-10 h).,Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698163/),h,8-10,181897,DB00361,Vinorelbine
,3698163,clearance,"We have also studied navelbine kinetics in cancer patients entered in recent navelbine clinical trials and found that navelbine pharmacokinetics are characterized by fast and extensive distribution, high clearance (0.92 +/- 0.27 1 h-1 kg-1), and a relatively long terminal half-life (31.2 +/- 4.4 h).",Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698163/),[1] / [h·kg],0.92,181898,DB00361,Vinorelbine
,3698163,terminal half-life,"We have also studied navelbine kinetics in cancer patients entered in recent navelbine clinical trials and found that navelbine pharmacokinetics are characterized by fast and extensive distribution, high clearance (0.92 +/- 0.27 1 h-1 kg-1), and a relatively long terminal half-life (31.2 +/- 4.4 h).",Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698163/),h,31.2,181899,DB00361,Vinorelbine
,18306910,drug,"These differences were not clinically significant, however the drug bioavailability, which was fixed to 0.35 in the simulation, might be highly variable among subjects contributing to a large extent to the observed variability in drug toxicity.",Chemotherapy-induced myelosuppression by vinorelbine: a comparison between different dose schedules by simulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18306910/),,0.35,182398,DB00361,Vinorelbine
,18306910,bioavailability,"These differences were not clinically significant, however the drug bioavailability, which was fixed to 0.35 in the simulation, might be highly variable among subjects contributing to a large extent to the observed variability in drug toxicity.",Chemotherapy-induced myelosuppression by vinorelbine: a comparison between different dose schedules by simulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18306910/),,0.35,182399,DB00361,Vinorelbine
,12649112,MTD,The MTD of vinflunine was achieved at 400 mg/m(2) every 3 weeks.,Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649112/),,400,187271,DB00361,Vinorelbine
,16428494,Cl(TB),"A higher mean i.v. Cl(TB) was observed (1.75 +/- 1.0 L/h/kg) compared with adult reports, with a mean t(1/2B) of 16.5 +/- 9.7 hours.",Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16428494/),[l] / [h·kg],1.75,187914,DB00361,Vinorelbine
,16428494,t(1/2B),"A higher mean i.v. Cl(TB) was observed (1.75 +/- 1.0 L/h/kg) compared with adult reports, with a mean t(1/2B) of 16.5 +/- 9.7 hours.",Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16428494/),h,16.5,187915,DB00361,Vinorelbine
,16428494,oral bioavailability,Mean oral bioavailability was 28.5 +/- 22.5%.,Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16428494/),%,28.5,187916,DB00361,Vinorelbine
,16428494,apparent oral clearance,The apparent oral clearance (12.1 +/- 13.0 L/h/kg) and volume of distribution (69.4 +/- 30.6 L/kg) were substantially higher than in adults given similar oral doses.,Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16428494/),[l] / [h·kg],12.1,187917,DB00361,Vinorelbine
,16428494,volume of distribution,The apparent oral clearance (12.1 +/- 13.0 L/h/kg) and volume of distribution (69.4 +/- 30.6 L/kg) were substantially higher than in adults given similar oral doses.,Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16428494/),[l] / [kg],69.4,187918,DB00361,Vinorelbine
,16428494,maximum tolerated dose,"The maximum tolerated dose in children without bone marrow involvement was 30 mg/m(2), similar to that reported in adults, with myelosuppression being the dose-limiting toxicity.",Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16428494/),[mg] / [m(2],30,187919,DB00361,Vinorelbine
,11521794,overall response rate,"Activity was observed at all dose levels and at all metastatic sites, with an overall response rate of 71% (95% CI: 52.0%-85.8%).",Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11521794/),%,71,192822,DB00361,Vinorelbine
,11521794,time to progression,The median time to progression was 31.4 weeks (95% CI: 12-48 weeks) and median survival was 15.6 months (95% CI: 2.6-26.6 months).,Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11521794/),weeks,31.4,192823,DB00361,Vinorelbine
,11521794,survival,The median time to progression was 31.4 weeks (95% CI: 12-48 weeks) and median survival was 15.6 months (95% CI: 2.6-26.6 months).,Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11521794/),month,15.6,192824,DB00361,Vinorelbine
,29956056,overall survival,"Results Median treatment duration and overall survival were 15 (range 1.3-144) and 32.3 weeks, respectively; fourty-eight (60%) patients experienced clinical benefit.",Oral Metronomic Vinorelbine (OMV) in elderly or pretreated patients with advanced non small cell lung cancer: outcome and pharmacokinetics in the real world. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29956056/),weeks,32.3,193972,DB00361,Vinorelbine
,21342795,flow-rate,"The chromatographic separation was achieved on a Spursil polar-modified C(18) column (50 mm×2.1 mm, 3 μm, Dikma Technologies) with an isocratic mobile phase of a 75:25 (v/v) acetonitrile-4 mmol/L ammonium formate (pH 3.0) mixture at a flow-rate of 0.4 mL/min.",Rapid and sensitive determination of vinorelbine in human plasma by liquid chromatography-tandem mass spectrometry and its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21342795/),[ml] / [min],0.4,194377,DB00361,Vinorelbine
,8877249,bioavailability,The bioavailability of a liquid filled gelatin capsule ranges between 12 and 59% with a mean value of 27% [standard deviation (SD) 12%].,Clinical pharmacokinetics of vinorelbine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877249/),%,27,195585,DB00361,Vinorelbine
,8877249,unbound blood fraction,"In vitro, vinorelbine is mainly distributed into the blood cells, especially platelets (78%) and lymphocytes (4.8%) The unbound blood fraction is around 2%.",Clinical pharmacokinetics of vinorelbine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877249/),%,2,195586,DB00361,Vinorelbine
,8877249,amount of radioactivity,"Faecal elimination has been demonstrated in 2 patients who were administered 3H-labelled vinorelbine; the amount of radioactivity recovered in the faeces was 33.9 and 58.4% for the 2 patients, respectively.",Clinical pharmacokinetics of vinorelbine. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877249/),%,33.9,195587,DB00361,Vinorelbine
,8877249,amount of radioactivity,"Faecal elimination has been demonstrated in 2 patients who were administered 3H-labelled vinorelbine; the amount of radioactivity recovered in the faeces was 33.9 and 58.4% for the 2 patients, respectively.",Clinical pharmacokinetics of vinorelbine. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877249/),%,58.4,195588,DB00361,Vinorelbine
,8877249,terminal half-life (t1/2),The pharmacokinetic profile of vinorelbine is often described as a 3-compartment model characterised by a long terminal half-life (t1/2) that varies between 20 and 40 hours and a large apparent volume of distribution (Vd) of around 70 L/kg.,Clinical pharmacokinetics of vinorelbine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877249/),h,20 and 40,195589,DB00361,Vinorelbine
,8877249,apparent volume of distribution (Vd),The pharmacokinetic profile of vinorelbine is often described as a 3-compartment model characterised by a long terminal half-life (t1/2) that varies between 20 and 40 hours and a large apparent volume of distribution (Vd) of around 70 L/kg.,Clinical pharmacokinetics of vinorelbine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877249/),[l] / [kg],70,195590,DB00361,Vinorelbine
,8877249,Systemic clearance,Systemic clearance ranges between 72.54 and 89.46 L/h (1209 and 1491 ml/min) when determined by high performance liquid chromatography and is higher than that reported by radioimmunoassay [46.2 L/h (770 ml/min)].,Clinical pharmacokinetics of vinorelbine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877249/),[l] / [h],72.54 and 89.46,195591,DB00361,Vinorelbine
,8877249,Systemic clearance,Systemic clearance ranges between 72.54 and 89.46 L/h (1209 and 1491 ml/min) when determined by high performance liquid chromatography and is higher than that reported by radioimmunoassay [46.2 L/h (770 ml/min)].,Clinical pharmacokinetics of vinorelbine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877249/),[ml] / [min],1209 and 1491,195592,DB00361,Vinorelbine
,8877249,Systemic clearance,Systemic clearance ranges between 72.54 and 89.46 L/h (1209 and 1491 ml/min) when determined by high performance liquid chromatography and is higher than that reported by radioimmunoassay [46.2 L/h (770 ml/min)].,Clinical pharmacokinetics of vinorelbine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877249/),[l] / [h],46.2,195593,DB00361,Vinorelbine
,8877249,t1/2,"In children, vinorelbine seems to display a shorter t1/2 (14.7 hours) than that found in adults.",Clinical pharmacokinetics of vinorelbine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877249/),h,14.7,195594,DB00361,Vinorelbine
,8877249,systemic clearance,"In addition, the systemic clearance is highly variable [from 12 to 93.96 L/h/m2 (200 to 1566 ml/min/m2)].",Clinical pharmacokinetics of vinorelbine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877249/),[l] / [h·m2],12 to 93.96,195595,DB00361,Vinorelbine
,8877249,systemic clearance,"In addition, the systemic clearance is highly variable [from 12 to 93.96 L/h/m2 (200 to 1566 ml/min/m2)].",Clinical pharmacokinetics of vinorelbine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877249/),[ml] / [m2·min],200 to 1566,195596,DB00361,Vinorelbine
,4016723,maximal tolerated dose,The maximal tolerated dose appears to be about 43 mg/m2.,Phase I pharmacologic study of a new Vinca alkaloid: navelbine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4016723/),[mg] / [m2],43,196957,DB00361,Vinorelbine
,4016723,elimination half-life,"Pharmacokinetics, studied with a radioimmunoassay (RIA) method, suggested an elimination half-life of 30 h and a plasma clearance of 75 l/h.",Phase I pharmacologic study of a new Vinca alkaloid: navelbine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4016723/),h,30,196958,DB00361,Vinorelbine
,4016723,plasma clearance,"Pharmacokinetics, studied with a radioimmunoassay (RIA) method, suggested an elimination half-life of 30 h and a plasma clearance of 75 l/h.",Phase I pharmacologic study of a new Vinca alkaloid: navelbine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4016723/),[l] / [h],75,196959,DB00361,Vinorelbine
,22967996,OR rate,The OR rate in assessable phase II patients was 41% (no prior lapatinib) and 8% (prior lapatinib).,Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22967996/),%,41,198109,DB00361,Vinorelbine
,22967996,OR rate,The OR rate in assessable phase II patients was 41% (no prior lapatinib) and 8% (prior lapatinib).,Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22967996/),%,8,198110,DB00361,Vinorelbine
,7849233,relative bioavailabilities,"The relative bioavailabilities (solution versus powder) were, respectively, 286.0% and 268.0% as estimated from experimental (0-72 h) and extrapolated (0-infinity) AUC.",Relative bioavailability of two oral formulations of navelbine in cancer patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7849233/),%,286.0,200413,DB00361,Vinorelbine
,7849233,relative bioavailabilities,"The relative bioavailabilities (solution versus powder) were, respectively, 286.0% and 268.0% as estimated from experimental (0-72 h) and extrapolated (0-infinity) AUC.",Relative bioavailability of two oral formulations of navelbine in cancer patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7849233/),%,268.0,200414,DB00361,Vinorelbine
,10914711,Area under the plasma-concentration time curve (AUC),Area under the plasma-concentration time curve (AUC) normalized to a 30 mg/m2 administered dose averaged 0.89 mg/liter x h (coefficient of variation = 23.7%).,Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10914711/),[mg] / [h·l],0.89,203196,DB00361,Vinorelbine
,10914711,total plasma clearance,The total plasma clearance averaged 0.93 liter/h/kg (0.61-1.83 liter/h/kg; coefficient of variation = 38.6%).,Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10914711/),[l] / [h·kg],0.93,203197,DB00361,Vinorelbine
,10914711,elimination half-life,The elimination half-life was 38.1 +/- 5.8 h.,Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10914711/),h,38.1,203198,DB00361,Vinorelbine
,9653499,overall response rate,Vinorelbine (VNR) is highly active in metastatic breast cancer (MBC) and has shown an overall response rate of 40%-50% as first-line treatment.,Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: a phase I-II clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653499/),%,40,203676,DB00361,Vinorelbine
,9653499,overall response rate,Vinorelbine (VNR) is highly active in metastatic breast cancer (MBC) and has shown an overall response rate of 40%-50% as first-line treatment.,Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: a phase I-II clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653499/),%,50,203677,DB00361,Vinorelbine
,9653499,overall response rate,"The overall response rate was 36.5% with a CR rate of 4.8% (two of 41 patients, all at the highest dose level) and a PR rate of 31.7% (13 of 41 patients).",Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: a phase I-II clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653499/),%,36.5,203678,DB00361,Vinorelbine
,9653499,CR rate,"The overall response rate was 36.5% with a CR rate of 4.8% (two of 41 patients, all at the highest dose level) and a PR rate of 31.7% (13 of 41 patients).",Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: a phase I-II clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653499/),%,4.8,203679,DB00361,Vinorelbine
,9653499,PR rate,"The overall response rate was 36.5% with a CR rate of 4.8% (two of 41 patients, all at the highest dose level) and a PR rate of 31.7% (13 of 41 patients).",Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: a phase I-II clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653499/),%,31.7,203680,DB00361,Vinorelbine
,9653499,response duration,The median response duration was 7.0 months (range 2-13 months).,Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: a phase I-II clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653499/),month,7.0,203681,DB00361,Vinorelbine
,20641009,flow rate,The LC flow rate was set to 0.28 mL/min and the gradient (solvent B concentration) was processed from 40 to 90%.,Sensitive measurement of vinorelbine in dog plasma by liquid chromatography-electrospray ionization tandem mass spectrometry utilizing transitions from double-charged precursor ions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20641009/),[ml] / [min],0.28,204130,DB00361,Vinorelbine
,9060524,overall response rate,The overall response rate was 40% (17 of 42; all partial responders).,Phase I study of vinorelbine and ifosfamide in advanced non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9060524/),%,40,205517,DB00361,Vinorelbine
,27330293,zeta potential,"The obtained BJO-CN had a spherical morphology with a positive zeta potential of 18.9 mV and an average particle size of 42.36 nm, showing high colloidal stability.","Preparation, characterization, and evaluation of antitumor effect of Brucea javanica oil cationic nanoemulsions. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27330293/),m,18.9,206323,DB00361,Vinorelbine
,27330293,drug loading,"The drug loading of BJO-CN was 91.83 mg·mL(-1), determined by high-performance liquid chromatography with precolumn derivatization.","Preparation, characterization, and evaluation of antitumor effect of Brucea javanica oil cationic nanoemulsions. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27330293/),[mg] / [ml],91.83,206324,DB00361,Vinorelbine
,15235341,area under the curve [AUC],"We present long-term results of a phase II trial of induction chemotherapy (IC) with uracilftegafur (UFT) 200 mg/m orally days 1 to 21, vinorelbine 25 mg/m intravenously (IV) days 1 and 8, and cisplatin 100 mg/m IV day 1 (UFTVP) each for 21 days for 4 courses, followed by radiotherapy concomitant with UFT 100 mg/m orally daily and carboplatin (area under the curve [AUC] = 0.5 IV weekly) (RT/ UFTJ), without surgery to the primary site if response, in patients (pts) with resectable locally advanced squamous cell carcinoma of the larynx and hypopharynx.","Long-term results of a phase II trial of induction chemotherapy with uracil-ftegafur (UFT), vinorelbine, and cisplatin (UFTVP) followed by radiotherapy concomitant with UFT and carboplatin (RT/UFTJ) in a primary site preservation setting for resectable locally advanced squamous cell carcinoma of larynx and hypopharynx. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15235341/),,0.5,219630,DB00361,Vinorelbine
,11822766,Tmax,"Oral vinorelbine was rapidly absorbed at 80 mg/m2 (Tmax 1.4 +/- 0.7 h) and showed a bioavailability of 43 +/- 14, and close to 40% based on AUC(last) and AUC(inf), respectively.",Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11822766/),h,1.4,220094,DB00361,Vinorelbine
,11822766,bioavailability,"Oral vinorelbine was rapidly absorbed at 80 mg/m2 (Tmax 1.4 +/- 0.7 h) and showed a bioavailability of 43 +/- 14, and close to 40% based on AUC(last) and AUC(inf), respectively.",Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11822766/),%,43,220095,DB00361,Vinorelbine
,11822766,bioavailability,"Oral vinorelbine was rapidly absorbed at 80 mg/m2 (Tmax 1.4 +/- 0.7 h) and showed a bioavailability of 43 +/- 14, and close to 40% based on AUC(last) and AUC(inf), respectively.",Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11822766/),%,40,220096,DB00361,Vinorelbine
,11822766,absolute bioavailability,"The absolute bioavailability of the oral vinorelbine (new, soft gelatine capsule) was close to 40%.",Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11822766/),%,40,220097,DB00361,Vinorelbine
,8339259,"dissociation constant, Kd","The gamma-emitting probe used in the RIA, 125I-(deacetyl-O4-vinblastine)-tyramine, bound very tightly to the monoclonal antibody (dissociation constant, Kd = 2.5 x 10(-11) M), demonstrating a high affinity mainly directed toward the catharantine nucleus (vindesine, vincristine, vinblastine, 100% cross-reactivity; vinorelbine, 0.3% cross-reactivity).",Human pharmacokinetics of a new Vinca alkaloid S 12363 with use of a monoclonal antibody-based radio- or enzyme immunoassay. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8339259/),M,2.5 x 10(-11),222912,DB00361,Vinorelbine
,8339259,terminal half-life; t1/2 gamma,"As determined by RIA, the S 12363 plasma profile was triphasic with a terminal half-life; t1/2 gamma = 49 +/- 16 h, a plasma clearance, CL = 0.14 +/- 0.04 liter/h/kg, and a volume of distribution at steady state, Vdss = 5.0 +/- 2.8 liter/kg.",Human pharmacokinetics of a new Vinca alkaloid S 12363 with use of a monoclonal antibody-based radio- or enzyme immunoassay. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8339259/),h,49,222913,DB00361,Vinorelbine
,8339259,"plasma clearance, CL","As determined by RIA, the S 12363 plasma profile was triphasic with a terminal half-life; t1/2 gamma = 49 +/- 16 h, a plasma clearance, CL = 0.14 +/- 0.04 liter/h/kg, and a volume of distribution at steady state, Vdss = 5.0 +/- 2.8 liter/kg.",Human pharmacokinetics of a new Vinca alkaloid S 12363 with use of a monoclonal antibody-based radio- or enzyme immunoassay. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8339259/),[l] / [h·kg],0.14,222914,DB00361,Vinorelbine
,8339259,"volume of distribution at steady state, Vdss","As determined by RIA, the S 12363 plasma profile was triphasic with a terminal half-life; t1/2 gamma = 49 +/- 16 h, a plasma clearance, CL = 0.14 +/- 0.04 liter/h/kg, and a volume of distribution at steady state, Vdss = 5.0 +/- 2.8 liter/kg.",Human pharmacokinetics of a new Vinca alkaloid S 12363 with use of a monoclonal antibody-based radio- or enzyme immunoassay. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8339259/),[l] / [kg],5.0,222915,DB00361,Vinorelbine
,27730471,tumor-to-muscle ratio (T/M),"The tumor-to-muscle ratio (T/M) derived from 3'-dexoy-3'-[18F]fluorothymidine ([18F]FLT) micro positron emission tomography (PET) images of D1V1- and D1fV1-treated mice and the controls on day 7 was 6.88 ± 0.54, 7.50 ± 0.84, and 9.87 ± 0.73, respectively, suggesting that D1V1 is a more efficacious regimen against CT-26 xenografts.",Monitoring Tumor Response after Liposomal Doxorubicin in Combination with Liposomal Vinorelbine Treatment Using 3'-Deoxy-3'-[18F]Fluorothymidine PET. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27730471/),,6.88,226135,DB00361,Vinorelbine
,27730471,tumor-to-muscle ratio (T/M),"The tumor-to-muscle ratio (T/M) derived from 3'-dexoy-3'-[18F]fluorothymidine ([18F]FLT) micro positron emission tomography (PET) images of D1V1- and D1fV1-treated mice and the controls on day 7 was 6.88 ± 0.54, 7.50 ± 0.84, and 9.87 ± 0.73, respectively, suggesting that D1V1 is a more efficacious regimen against CT-26 xenografts.",Monitoring Tumor Response after Liposomal Doxorubicin in Combination with Liposomal Vinorelbine Treatment Using 3'-Deoxy-3'-[18F]Fluorothymidine PET. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27730471/),,7.50,226136,DB00361,Vinorelbine
,27730471,tumor-to-muscle ratio (T/M),"The tumor-to-muscle ratio (T/M) derived from 3'-dexoy-3'-[18F]fluorothymidine ([18F]FLT) micro positron emission tomography (PET) images of D1V1- and D1fV1-treated mice and the controls on day 7 was 6.88 ± 0.54, 7.50 ± 0.84, and 9.87 ± 0.73, respectively, suggesting that D1V1 is a more efficacious regimen against CT-26 xenografts.",Monitoring Tumor Response after Liposomal Doxorubicin in Combination with Liposomal Vinorelbine Treatment Using 3'-Deoxy-3'-[18F]Fluorothymidine PET. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27730471/),,9.87,226137,DB00361,Vinorelbine
,7740337,response rate,"In one study of 98 advanced breast cancer patients aged 65 years and older with limited prior therapy, the response rate of oral vinorelbine was 24% (complete response, 5%; partial response, 19%).",Oral vinorelbine (Navelbine) in the treatment of advanced breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7740337/),%,24,226796,DB00361,Vinorelbine
,7740337,response rate,"In a study of 131 heavily pretreated patients with advanced breast cancer, the response rate of oral vinorelbine was 11% (complete response, 0%; partial response, 11%).",Oral vinorelbine (Navelbine) in the treatment of advanced breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7740337/),%,11,226797,DB00361,Vinorelbine
,7740337,response rate,"In a study of 131 heavily pretreated patients with advanced breast cancer, the response rate of oral vinorelbine was 11% (complete response, 0%; partial response, 11%).",Oral vinorelbine (Navelbine) in the treatment of advanced breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7740337/),%,0,226798,DB00361,Vinorelbine
,16303864,response rate,"Objective responses were reported in 18 patients (three complete responses and 15 partial responses), yielding a response rate of 40.9% in the intention-to-treat population according to the investigator assessment.",Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16303864/),%,40.9,227968,DB00361,Vinorelbine
,12902890,overall response rate,"The overall response rate was 49%, which included 3 of 29 complete responses (10%) and 11 of 29 partial responses (38%).",Docetaxel and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12902890/),%,49,229295,DB00361,Vinorelbine
,12902890,complete,"Median complete and partial response durations were 20+ and 5.5 months, respectively.",Docetaxel and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12902890/),month,20,229296,DB00361,Vinorelbine
,12902890,partial response durations,"Median complete and partial response durations were 20+ and 5.5 months, respectively.",Docetaxel and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12902890/),month,5.5,229297,DB00361,Vinorelbine
,12902890,Overall median survival,"Overall median survival was 10 months (range, 2-30+).",Docetaxel and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12902890/),month,10,229298,DB00361,Vinorelbine
,9135505,apparent volume of distribution,"Vinorelbine showed a large apparent volume of distribution (mean 23.4 l/kg), a long terminal half-life (mean 26.2 h) and a large systemic clearance rate (mean 1.2 l/kg).",Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9135505/),[l] / [kg],23.4,230953,DB00361,Vinorelbine
,9135505,terminal half-life,"Vinorelbine showed a large apparent volume of distribution (mean 23.4 l/kg), a long terminal half-life (mean 26.2 h) and a large systemic clearance rate (mean 1.2 l/kg).",Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9135505/),h,26.2,230954,DB00361,Vinorelbine
,9135505,systemic clearance rate,"Vinorelbine showed a large apparent volume of distribution (mean 23.4 l/kg), a long terminal half-life (mean 26.2 h) and a large systemic clearance rate (mean 1.2 l/kg).",Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9135505/),[l] / [kg],1.2,230955,DB00361,Vinorelbine
,27541873,"tissue/plasma partition coefficient, Kp,uu","Unbound vinorelbine tissue/plasma partition coefficient, Kp,uu, equaled ~1.0 in systemic metastases, but 0.03-0.22 in brain metastases, documenting restricted equilibration.",Vinorelbine Delivery and Efficacy in the MDA-MB-231BR Preclinical Model of Brain Metastases of Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27541873/),,1.0,233888,DB00361,Vinorelbine
,27541873,"tissue/plasma partition coefficient, Kp,uu","Unbound vinorelbine tissue/plasma partition coefficient, Kp,uu, equaled ~1.0 in systemic metastases, but 0.03-0.22 in brain metastases, documenting restricted equilibration.",Vinorelbine Delivery and Efficacy in the MDA-MB-231BR Preclinical Model of Brain Metastases of Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27541873/),,0.03-0.22,233889,DB00361,Vinorelbine
,27541873,"Kp,uu","In select sub-regions of highest drug-uptake brain metastases, Kp,uu approached 1.0, indicating complete focal barrier breakdown.",Vinorelbine Delivery and Efficacy in the MDA-MB-231BR Preclinical Model of Brain Metastases of Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27541873/),,1.0,233890,DB00361,Vinorelbine
,27541873,IC50,The in vivo unbound vinorelbine IC50 for TUNEL-positive staining (56 nM) was 4-fold higher than that measured in vitro (14 nM).,Vinorelbine Delivery and Efficacy in the MDA-MB-231BR Preclinical Model of Brain Metastases of Breast Cancer. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27541873/),nM,56,233891,DB00361,Vinorelbine
,27541873,IC50,The in vivo unbound vinorelbine IC50 for TUNEL-positive staining (56 nM) was 4-fold higher than that measured in vitro (14 nM).,Vinorelbine Delivery and Efficacy in the MDA-MB-231BR Preclinical Model of Brain Metastases of Breast Cancer. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27541873/),nM,14,233892,DB00361,Vinorelbine
,9213325,overall response rate,"Responses were seen at all dose levels, with an 80% overall response rate at the higher recommended dose; the overall response rate for patients at all dose levels was 66%.",Docetaxel combined with vinorelbine: phase I results and new study designs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9213325/),%,66,235338,DB00361,Vinorelbine
,12045458,CL,"The population average parameters and the interindividual variabilities (CV%) were: CL=47.1 l/h (31.7%), V=16.6 l (64%), k21=0.776 h-1 (20%), k31=0.0346 h-1 (15.2%), alpha=0.431 h-1 (6.84%) and beta=0.0167 h-1 (25%).",A limited-sampling strategy to estimate individual pharmacokinetic parameters of vinorelbine in elderly patients with advanced metastatic cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12045458/),[l] / [h],47.1,236034,DB00361,Vinorelbine
,12045458,V,"The population average parameters and the interindividual variabilities (CV%) were: CL=47.1 l/h (31.7%), V=16.6 l (64%), k21=0.776 h-1 (20%), k31=0.0346 h-1 (15.2%), alpha=0.431 h-1 (6.84%) and beta=0.0167 h-1 (25%).",A limited-sampling strategy to estimate individual pharmacokinetic parameters of vinorelbine in elderly patients with advanced metastatic cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12045458/),l,16.6,236035,DB00361,Vinorelbine
,12045458,k21,"The population average parameters and the interindividual variabilities (CV%) were: CL=47.1 l/h (31.7%), V=16.6 l (64%), k21=0.776 h-1 (20%), k31=0.0346 h-1 (15.2%), alpha=0.431 h-1 (6.84%) and beta=0.0167 h-1 (25%).",A limited-sampling strategy to estimate individual pharmacokinetic parameters of vinorelbine in elderly patients with advanced metastatic cancer. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12045458/),1/[h],0.776,236036,DB00361,Vinorelbine
,12045458,k31,"The population average parameters and the interindividual variabilities (CV%) were: CL=47.1 l/h (31.7%), V=16.6 l (64%), k21=0.776 h-1 (20%), k31=0.0346 h-1 (15.2%), alpha=0.431 h-1 (6.84%) and beta=0.0167 h-1 (25%).",A limited-sampling strategy to estimate individual pharmacokinetic parameters of vinorelbine in elderly patients with advanced metastatic cancer. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12045458/),1/[h],0.0346,236037,DB00361,Vinorelbine
,12045458,alpha,"The population average parameters and the interindividual variabilities (CV%) were: CL=47.1 l/h (31.7%), V=16.6 l (64%), k21=0.776 h-1 (20%), k31=0.0346 h-1 (15.2%), alpha=0.431 h-1 (6.84%) and beta=0.0167 h-1 (25%).",A limited-sampling strategy to estimate individual pharmacokinetic parameters of vinorelbine in elderly patients with advanced metastatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12045458/),1/[h],0.431,236038,DB00361,Vinorelbine
,12045458,beta,"The population average parameters and the interindividual variabilities (CV%) were: CL=47.1 l/h (31.7%), V=16.6 l (64%), k21=0.776 h-1 (20%), k31=0.0346 h-1 (15.2%), alpha=0.431 h-1 (6.84%) and beta=0.0167 h-1 (25%).",A limited-sampling strategy to estimate individual pharmacokinetic parameters of vinorelbine in elderly patients with advanced metastatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12045458/),1/[h],0.0167,236039,DB00361,Vinorelbine
,12172972,IC50,"Although tumor cell proliferation and accumulation of cells in the G2 phase of the cell cycle were similarly affected by the two compounds after a continuous exposure (IC50 values of 30-50 n M), S 30972-1 was about tenfold less potent than S 16020-2 after short exposures.",Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12172972/),M·n,30-50,239299,DB00361,Vinorelbine
,8258199,maximal,"The serum concentrations decreased rapidly from a maximal value of 208.6 ng/ml (SD, 111.7 ng/ml).",Biliary elimination and pharmacokinetics of vinorelbine in micropigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8258199/),[ng] / [ml],208.6,239485,DB00361,Vinorelbine
,8258199,half-life,"The mean half-life was 10.9 h (SD, 8.6 h) and the mean AUC0-48 h was 292.8 ng ml-1 h (SD, 79.4 ng ml-1 h).",Biliary elimination and pharmacokinetics of vinorelbine in micropigs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8258199/),h,10.9,239486,DB00361,Vinorelbine
,8258199,AUC0-48 h,"The mean half-life was 10.9 h (SD, 8.6 h) and the mean AUC0-48 h was 292.8 ng ml-1 h (SD, 79.4 ng ml-1 h).",Biliary elimination and pharmacokinetics of vinorelbine in micropigs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8258199/),[h·ng] / [ml],292.8,239487,DB00361,Vinorelbine
,8258199,bile concentrations,"The bile concentrations were high, amounting to 16.0 micrograms/ml (range, 5.4-27.7 micrograms/ml).",Biliary elimination and pharmacokinetics of vinorelbine in micropigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8258199/),[μg] / [ml],16.0,239488,DB00361,Vinorelbine
,8258199,bi,"The 0- to 48-h biliary excretion of unchanged NVB accounted for 25.8% (SD, 5.7%) of the injected dose, with 21.5% (SD, 4.0%) being eliminated during the 0- to 8-h period.",Biliary elimination and pharmacokinetics of vinorelbine in micropigs. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8258199/),%,25.8,239489,DB00361,Vinorelbine
,8311488,maximum tolerated dose (MTD),The maximum tolerated dose (MTD) was 30 mg/m2 in single administration and 25 mg/m2 in the repeated administration provided that administration is made weekly for 4 consecutive weeks.,"[Phase I clinical study on new vinca alkaloid derivative, KW-2307 (vinorelbine). KW-2307 Study Group]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8311488/),[mg] / [m2],30,241958,DB00361,Vinorelbine
,8311488,maximum tolerated dose (MTD),The maximum tolerated dose (MTD) was 30 mg/m2 in single administration and 25 mg/m2 in the repeated administration provided that administration is made weekly for 4 consecutive weeks.,"[Phase I clinical study on new vinca alkaloid derivative, KW-2307 (vinorelbine). KW-2307 Study Group]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8311488/),[mg] / [m],25,241959,DB00361,Vinorelbine
,8311488,half-life,The pharmacokinetics of KW-2307 in blood after single administration showed a triphasic disappearance pattern with half-life of about 20 to 60 hrs.,"[Phase I clinical study on new vinca alkaloid derivative, KW-2307 (vinorelbine). KW-2307 Study Group]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8311488/),h,20 to 60,241960,DB00361,Vinorelbine
,3359064,total plasma clearance,"Following IV bolus injection, the mean pharmacokinetic parameters are: total plasma clearance: 0.53 l/h-1kg-1, 0.72 l/h-1kg-1 and apparent elimination half-life: 23.2 h, 39.5 h for VDS and NVB, respectively.",[Clinical pharmacokinetics of vinca alkaloids]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3359064/),[l] / [h],0.53,249772,DB00361,Vinorelbine
,3359064,total plasma clearance,"Following IV bolus injection, the mean pharmacokinetic parameters are: total plasma clearance: 0.53 l/h-1kg-1, 0.72 l/h-1kg-1 and apparent elimination half-life: 23.2 h, 39.5 h for VDS and NVB, respectively.",[Clinical pharmacokinetics of vinca alkaloids]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3359064/),[l] / [h],0.72,249773,DB00361,Vinorelbine
,3359064,apparent elimination half-life,"Following IV bolus injection, the mean pharmacokinetic parameters are: total plasma clearance: 0.53 l/h-1kg-1, 0.72 l/h-1kg-1 and apparent elimination half-life: 23.2 h, 39.5 h for VDS and NVB, respectively.",[Clinical pharmacokinetics of vinca alkaloids]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3359064/),h,23.2,249774,DB00361,Vinorelbine
,3359064,apparent elimination half-life,"Following IV bolus injection, the mean pharmacokinetic parameters are: total plasma clearance: 0.53 l/h-1kg-1, 0.72 l/h-1kg-1 and apparent elimination half-life: 23.2 h, 39.5 h for VDS and NVB, respectively.",[Clinical pharmacokinetics of vinca alkaloids]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3359064/),h,39.5,249775,DB00361,Vinorelbine
,26801247,PFS,"Median PFS for all 50 patients was 5.5 months (95% confidence interval, 4.1-6.7).",Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26801247/),month,5.5,251225,DB00361,Vinorelbine
,30542768,OS,"Median OS and treatment duration were 27 weeks (range 1.3-183) and 15 weeks (range 1.3-144), respectively.",Clinical outcomes of oral metronomic vinorelbine in advanced non-small cell lung cancer: correlations with pharmacokinetics and MDR1 polymorphisms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30542768/),weeks,27,251670,DB00361,Vinorelbine
,21107682,progression-free survival,"ORR was 19.1%, with a disease control rate of 83.0% and median progression-free survival of 30.7 weeks.",Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21107682/),weeks,30.7,252471,DB00361,Vinorelbine
,16357174,t(1/2),Pharmacokinetic and biodistribution studies confirmed long circulation times (t(1/2) = 21 hours) and efficient accumulation in tumors (up to 15% ID/g) irrespective of the presence of the targeting ligand.,Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16357174/),h,21,253278,DB00361,Vinorelbine
,17541591,AUCs,"Mean AUCs were 1,230 +/- 290 and 1,216 +/- 521 ng/ml for i.v. and oral, respectively.",Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17541591/),[ng] / [ml],"1,230",254433,DB00361,Vinorelbine
,17541591,AUCs,"Mean AUCs were 1,230 +/- 290 and 1,216 +/- 521 ng/ml for i.v. and oral, respectively.",Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17541591/),[ng] / [ml],"1,216",254434,DB00361,Vinorelbine
,17541591,absolute bioavailability,"The absolute bioavailability was 37.8 +/- 16.0%, and close to the value from the first study (40%).",Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17541591/),%,37.8,254435,DB00361,Vinorelbine
,17541591,absolute bioavailability,"The absolute bioavailability was 37.8 +/- 16.0%, and close to the value from the first study (40%).",Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17541591/),%,40,254436,DB00361,Vinorelbine
,24365981,flow rate,"Chromatographic separation of these anticancer drugs was achieved with an isocratic mobile phase consisting of acetonitrile/aqueous buffer (10 mmol/L ammonium acetate and 0.1% formic acid in 70:30, vol/vol) at a flow rate of 0.25 mL/min in a short time (4.5 minutes).","Rapid and sensitive liquid chromatography coupled with electrospray ionization tandem mass spectrometry method for the analysis of paclitaxel, docetaxel, vinblastine, and vinorelbine in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24365981/),[ml] / [min],0.25,260934,DB00361,Vinorelbine
,6498821,systemic clearance,"Navelbine systemic clearance was estimated from the area under the concentration-time curves [1.9 +/- 0.5 (S.D.) liters/hr/kg] and was found to be larger than that of vinblastine (1.1 +/- 0.4 liters/hr/kg) measured under similar conditions (dose, 0.6 mg/kg).",Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5'-noranhydrovinblastine (navelbine). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498821/),[l] / [h·kg],1.9,261637,DB00361,Vinorelbine
,6498821,systemic clearance,"Navelbine systemic clearance was estimated from the area under the concentration-time curves [1.9 +/- 0.5 (S.D.) liters/hr/kg] and was found to be larger than that of vinblastine (1.1 +/- 0.4 liters/hr/kg) measured under similar conditions (dose, 0.6 mg/kg).",Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5'-noranhydrovinblastine (navelbine). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498821/),[l] / [h·kg],1.1,261638,DB00361,Vinorelbine
,6498821,area under the concentration-time curves,"Navelbine systemic clearance was estimated from the area under the concentration-time curves [1.9 +/- 0.5 (S.D.) liters/hr/kg] and was found to be larger than that of vinblastine (1.1 +/- 0.4 liters/hr/kg) measured under similar conditions (dose, 0.6 mg/kg).",Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5'-noranhydrovinblastine (navelbine). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498821/),[l] / [h·kg],1.9,261639,DB00361,Vinorelbine
,6498821,area under the concentration-time curves,"Navelbine systemic clearance was estimated from the area under the concentration-time curves [1.9 +/- 0.5 (S.D.) liters/hr/kg] and was found to be larger than that of vinblastine (1.1 +/- 0.4 liters/hr/kg) measured under similar conditions (dose, 0.6 mg/kg).",Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5'-noranhydrovinblastine (navelbine). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498821/),[l] / [h·kg],1.1,261640,DB00361,Vinorelbine
,6498821,Terminal half-lives,Terminal half-lives were 8.9 +/- 2.1 hr for navelbine and 8.1 +/- 2.6 hr for vinblastine.,Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5'-noranhydrovinblastine (navelbine). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498821/),h,8.9,261641,DB00361,Vinorelbine
,6498821,Terminal half-lives,Terminal half-lives were 8.9 +/- 2.1 hr for navelbine and 8.1 +/- 2.6 hr for vinblastine.,Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5'-noranhydrovinblastine (navelbine). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498821/),h,8.1,261642,DB00361,Vinorelbine
,8141830,half-life,"2. Plasma concentrations of drug-related radioactivity declined in a bi- or tri-exponential manner, initially rapidly and then slowly (half-life of 35 h or more).","Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141830/),h,35,263164,DB00361,Vinorelbine
,8141830,terminal half-lives,Unchanged drug concentrations declined with terminal half-lives of 35.8 h in rats and 34.5h in dogs: a terminal phase was not observed in mice.,"Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141830/),h,35.8,263165,DB00361,Vinorelbine
,8141830,terminal half-lives,Unchanged drug concentrations declined with terminal half-lives of 35.8 h in rats and 34.5h in dogs: a terminal phase was not observed in mice.,"Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141830/),h,34.5,263166,DB00361,Vinorelbine
,8141830,clearance,"KW-2307 can be characterised as a drug of high clearance (3.78, 1.73 and 1.20 l/h/kg in the mice, rats and dogs, respectively) and large volume of distribution (12.7, 41.9 and 49.6 l/kg in the mouse, rat and dog, respectively).","Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141830/),[l] / [h·kg],3.78,263167,DB00361,Vinorelbine
,8141830,clearance,"KW-2307 can be characterised as a drug of high clearance (3.78, 1.73 and 1.20 l/h/kg in the mice, rats and dogs, respectively) and large volume of distribution (12.7, 41.9 and 49.6 l/kg in the mouse, rat and dog, respectively).","Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141830/),[l] / [h·kg],1.73,263168,DB00361,Vinorelbine
,8141830,clearance,"KW-2307 can be characterised as a drug of high clearance (3.78, 1.73 and 1.20 l/h/kg in the mice, rats and dogs, respectively) and large volume of distribution (12.7, 41.9 and 49.6 l/kg in the mouse, rat and dog, respectively).","Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141830/),[l] / [h·kg],1.20,263169,DB00361,Vinorelbine
,8141830,volume of distribution,"KW-2307 can be characterised as a drug of high clearance (3.78, 1.73 and 1.20 l/h/kg in the mice, rats and dogs, respectively) and large volume of distribution (12.7, 41.9 and 49.6 l/kg in the mouse, rat and dog, respectively).","Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141830/),[l] / [kg],12.7,263170,DB00361,Vinorelbine
,8141830,volume of distribution,"KW-2307 can be characterised as a drug of high clearance (3.78, 1.73 and 1.20 l/h/kg in the mice, rats and dogs, respectively) and large volume of distribution (12.7, 41.9 and 49.6 l/kg in the mouse, rat and dog, respectively).","Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141830/),[l] / [kg],41.9,263171,DB00361,Vinorelbine
,8141830,volume of distribution,"KW-2307 can be characterised as a drug of high clearance (3.78, 1.73 and 1.20 l/h/kg in the mice, rats and dogs, respectively) and large volume of distribution (12.7, 41.9 and 49.6 l/kg in the mouse, rat and dog, respectively).","Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141830/),[l] / [kg],49.6,263172,DB00361,Vinorelbine
,8141830,accumulation ratio,"After repeated administrations for 21 days in the rat, the accumulation ratio for unchanged drug concentrations in plasma was 1.5.","Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141830/),,1.5,263173,DB00361,Vinorelbine
,8141830,binding,"3. The extent of binding of 3H-KW-2307 in vitro to proteins in the plasma of humans, dogs, rats and mice was 89, 90, 93 and 97%, respectively.","Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141830/),%,89,263174,DB00361,Vinorelbine
,8141830,binding,"3. The extent of binding of 3H-KW-2307 in vitro to proteins in the plasma of humans, dogs, rats and mice was 89, 90, 93 and 97%, respectively.","Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141830/),%,90,263175,DB00361,Vinorelbine
,8141830,binding,"3. The extent of binding of 3H-KW-2307 in vitro to proteins in the plasma of humans, dogs, rats and mice was 89, 90, 93 and 97%, respectively.","Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141830/),%,93,263176,DB00361,Vinorelbine
,8141830,binding,"3. The extent of binding of 3H-KW-2307 in vitro to proteins in the plasma of humans, dogs, rats and mice was 89, 90, 93 and 97%, respectively.","Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141830/),%,97,263177,DB00361,Vinorelbine
,12367795,area under the curve (AUC),"It consisted of vinorelbine at 15 mg/m(2) and carboplatin administered at an initial area under the curve (AUC) of 1.5, and increased by an AUC of 0.5 per dose level to a maximum AUC of 3, corresponding with an AUC of 6 per cycle of chemotherapy.",Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12367795/),,1.5,263280,DB00361,Vinorelbine
,12367795,AU,"It consisted of vinorelbine at 15 mg/m(2) and carboplatin administered at an initial area under the curve (AUC) of 1.5, and increased by an AUC of 0.5 per dose level to a maximum AUC of 3, corresponding with an AUC of 6 per cycle of chemotherapy.",Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12367795/),,0.5,263281,DB00361,Vinorelbine
,12367795,maximum AUC,"It consisted of vinorelbine at 15 mg/m(2) and carboplatin administered at an initial area under the curve (AUC) of 1.5, and increased by an AUC of 0.5 per dose level to a maximum AUC of 3, corresponding with an AUC of 6 per cycle of chemotherapy.",Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12367795/),,3,263282,DB00361,Vinorelbine
,12367795,AUC,"It consisted of vinorelbine at 15 mg/m(2) and carboplatin administered at an initial area under the curve (AUC) of 1.5, and increased by an AUC of 0.5 per dose level to a maximum AUC of 3, corresponding with an AUC of 6 per cycle of chemotherapy.",Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12367795/),1/[cycle],6,263283,DB00361,Vinorelbine
,12367795,AUC,The recommended phase II dose of carboplatin is an AUC of 3 on 2 consecutive weeks.,Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12367795/),,3,263284,DB00361,Vinorelbine
,12367795,survival,The median survival for the entire group and for patients with stage II/III disease was 13.5 months.,Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12367795/),month,13.5,263285,DB00361,Vinorelbine
,15668288,overall response rate,"In 30 patients evaluated for response and toxicity, the overall response rate was 37% and 10% of patients achieved stable disease.",Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15668288/),%,37,263607,DB00361,Vinorelbine
,15668288,time to progression,"Median time to progression and overall survival were 5.5 months (range 1-10) and 9 months (range 2-16), respectively.",Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15668288/),month,5.5,263608,DB00361,Vinorelbine
,15668288,overall survival,"Median time to progression and overall survival were 5.5 months (range 1-10) and 9 months (range 2-16), respectively.",Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15668288/),month,9,263609,DB00361,Vinorelbine
,15519515,disease control rate,"Six partial responses (11%) and 25 stable disease responses were recorded, with a disease control rate of 55%.","Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15519515/),%,55,264079,DB00361,Vinorelbine
,15519515,overall survival,Median overall survival was 8.2 months (95% Confidence Interval (CI) [6.2-11.3]).,"Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15519515/),month,8.2,264080,DB00361,Vinorelbine
,15519515,clinical benefit response rate,The clinical benefit response rate was 31% on 32 evaluable patients.,"Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15519515/),%,31,264081,DB00361,Vinorelbine
,24721203,m/z,"The ion transitions recorded in multiple reaction monitoring mode were m/z 754.6→123.8 for VDS and 779.4→323.3 for IS, respectively.",Validated HILIC-MS/MS assay for determination of vindesine in human plasma: Application to a population pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24721203/),,754.6,271193,DB00361,Vinorelbine
,24721203,m/z,"The ion transitions recorded in multiple reaction monitoring mode were m/z 754.6→123.8 for VDS and 779.4→323.3 for IS, respectively.",Validated HILIC-MS/MS assay for determination of vindesine in human plasma: Application to a population pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24721203/),,123.8,271194,DB00361,Vinorelbine
,24721203,m/z,"The ion transitions recorded in multiple reaction monitoring mode were m/z 754.6→123.8 for VDS and 779.4→323.3 for IS, respectively.",Validated HILIC-MS/MS assay for determination of vindesine in human plasma: Application to a population pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24721203/),,779.4,271195,DB00361,Vinorelbine
,11087081,Extraction recoveries,"Extraction recoveries from plasma and blood averaged 101 and 75%, respectively.",High-performance liquid chromatographic determination of vinorelbine in human plasma and blood: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11087081/),%,101,273888,DB00361,Vinorelbine
,11087081,Extraction recoveries,"Extraction recoveries from plasma and blood averaged 101 and 75%, respectively.",High-performance liquid chromatographic determination of vinorelbine in human plasma and blood: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11087081/),%,75,273889,DB00361,Vinorelbine
